 
 
 
 A prospective, double -masked, randomized, 
multi-center, active-controlled, parallel-group 
12-month study assessing the safety and 
ocular hypotensive efficacy of PG324 
Ophthalmic Solution compared to AR-13324 Ophthalmic Solution, 0.02% and Latanoprost 
Opht
halmic Solution, 0.005% in subjects with 
elevated intraocular pressure  
 
 
 
[STUDY_ID_REMOVED]  
 
12June2017 
 
PG324 Ophthalmic Solution  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
Confidential  Page 1 of 123 Clini
cal Study Protocol: PG324- CS30 1 
Study Title:  A prospective, double-masked, randomized, multi- center, 
active-controlled, parallel-group 12-month study assessing the safety 
and ocular hypotensive efficacy of PG324 Ophthalmic Solution compared to AR-13324 Ophthalmic Solution, 0.02% and Latanoprost Ophthalmic Solution, 0.005% in subject s with elevated intraocular 
pressure  
Study Number:  PG324 -CS30 1 
Study Phase:  3 
Product Name:  PG324 (AR -13324, 0.02% and latanoprost, 0.005%) Ophthalmic 
Solution  
Indicati on: Reduction of intraocular pressure in subject s with open -angle glaucoma  
or ocular hypertension  
Investigators:  Multi -center  
Sponsor:  Aerie Pharmaceuticals, Inc.  
Sponsor Contact:  135 US Highway 206, Suite 15  
Bedminster, NJ 07921 
(908) 470 -4320  
Medical  Monitor:  Richard A. Lewis, M.D.  
Date  
Original Protocol (Rev 0):  10 June 201 5 
Amendment 1 (Rev 1):  24 June 2015  
Amendment 2 (Rev 2):  
Amendment 3 (Rev 3):  
Amendment 4 (Rev 4):  12 April 2016 
05 January 2017 
12 June 2017 
Confi
dentiality Statement 
This document contains Aerie Pharmaceuticals®, Inc.’s (Aerie) information that is 
confidential, a trade secret and/or proprietary in nature.  It is loaned to you for your 
confidential use on behalf of Aerie and is not to be photocopied, disclosed or transmitted to 
any other person or party who is not covered by a Confidential Disclosure Agreement with 
Aerie.  As the Principal Investigator you are responsible for the safekeeping and return of this 
document to Aerie upon request.  You will be sent updated information and/or amendments 
as they become available.  
PG324 Ophthalmic Solution  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
Confidential  Page 28 of 123 4.Known hypersensitivity to an y component of the formulation , to latanoprost, or to topical anesthetic
5.Previous glaucoma intraocular surgery, including SLT  or ALT in either eye
6.Refractive surgery in either eye ( eg, radial keratotomy, PRK, LASIK, corneal cross -linking, etc.)
7.Ocular trauma within the six months prior to screening, or ocular surgery or non -refractive laser treatment
within the three months prior to screening
8.Recent or current evidence of ocular infection or inflammation in either eye.  Current evidence of clinically
significant blepharitis, keratitis, or conjunctivitis.  Additionally,  current evidence or  history  of herpes
simplex or zoster keratitis in either eye  at screening  is excluded .
9.Used ocular medication in either eye of any kind within 30 days of screening  and throughout the study ,
with the exception of a)  ocular hypotensive medications (which must be washed out according to the
provided schedule), b) lid scrubs (which may be used prior to, but not after screening) , c) lubricating drops
for dry eye (which may be used throughout the study) , or d) non-corticosteroid or non -vasoconstrictor
containing allergy drops and allergy drops that do not have a redness r eliever effect  as prescribed by the
Investigator
10.Mean central corneal thickness greater than 620 μm at screening
11.Any abnormality preventing reliable applanation tonometry of either eye (eg, keratoconus, etc.)
Systemic:
12.Clinically significant abnormalities in laboratory tests at screening
13.Clinically significant systemic disease ( eg, uncontrolled diabetes, myasthenia gravis, hepatic, renal,
endocrine or cardiovascular disorders) which might interfere with the study
14.Participation in any investigational study within 60 days prior to screening
15.Systemic medication that could have a substantial effect on IOP within 30 days prior to screening, or
anticipated during the study, including any corticosteroid -containing drug  regardless of route of
administration.
16.Women of childbearing potential who are pregnant, nursing, pl anning a pregnancy, or not using a
medically acceptable form of birth control.  An adult woman is considered to be of childbearing potential
unless she is one year post -menopausal or three months post -surgical sterilization.  All females of
childbearing potential must have a negative urine pregnancy test result at the screening examination and
must not intend to become pregnant during the study.
Study Population:  
A total of approximately 690 subject s will be enrolled in this study at approximately 60 clini cal sites, 
comprisi ng a total of approximately 230 subject s per treatment arm for each of 3 treatment arms.  Subject s who 
are enrolled in this study will be those at least 18  years of age with diagnosed open angle glaucoma (OAG) or 
ocular hypertension (OHT ), each of whom meets all inclusion criteria and none of the exclusion criteria.  
Investigational Product s, Dose, and Mode of Administration:  
•PG324 Ophthalmic Solution, 1 drop QD (PM) , OU
•AR-13324 Ophthalmic Solution, 0.02%, 1 drop QD (PM) , OU
•Latanoprost Ophthalmic Solution, 0.005%, 1 drop QD (PM) , OU
Duration of Treatment:   Subject s will dose for approximately 365 days 
Efficacy Assessments:  
The primary efficacy variable will be:  
•IOP measurements at 8:00, 10:00, and 16:00 hours at Week 2 (Day 15), Week 6 (Day 43), and Month 3
(Day 90) by Goldmann Applanation Tonometry
The primary efficacy outcome will be  the comparison of PG324 Ophthalmic Solution relative to each of its 
active components, AR -13324, 0.02% and latanoprost, 0.005%, for : 
PG324 Ophthalmic Solution   
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 31 of 123  
   
  
TABLE OF CONTENTS  
SYNOPSIS  ........................................................................................................................26  
LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS  ..............................35  
1. INTRODUCTION ....................................................................................................37  
1.1 Investigational Product .......................................................................................37  
1.2 Findings from Nonclinical and Clinical Studies  ................................................38  
1.3 Risks and Benefits to Human Subjec ts ..............................................................38  
2. STUDY OBJECTIVES  ............................................................................................38  
2.1 Primary Objectives  ..............................................................................................38  
2.2 Secondary Objectives ...........................................................................................39  
3. INVESTIGATIONAL PLAN  ..................................................................................39  
3.1 Overall Study Design and Plan ...........................................................................39  
3.2 Rationale for Study Design and Control Group ...............................................41  
3.3 Expected Duration of Subject Participation ......................................................41  
4. STUDY POPULATION SELECTI ON ...................................................................41  
4.1 Study Population  ..................................................................................................41  
4.2 Inclusion Criteria  .................................................................................................41  
4.3 Exclusion Criteria  ................................................................................................42  
4.4 Subject Enrollment  ..............................................................................................44  
5. STUDY TREATMENTS  ..........................................................................................44  
5.1 Description of Treatments  ...................................................................................44  
5.1.1  Investigational Product .................................................................................44  
5.1.2  Comparator Products  ....................................................................................44  
5.2 Treatments Administered  ...................................................................................44  
5.3 Selection and Timing of Dose for Each Subject  ................................................45  
5.4 Method of Assigning Subjects to Treatment Groups  .......................................45  
5.5 Masking  .................................................................................................................45  
5.6 Concomitant Therapy  ..........................................................................................46  
5.7 Restrictions  ...........................................................................................................47  
5.7.1  Prior Therapy  .................................................................................................47  
5.7.2  Fluid and Food Intake  ...................................................................................47  
5.7.3  Subject Activity Restrictions  .........................................................................48  
5.8 Treatment Compliance  ........................................................................................48  
5.9 Packaging and Labeling ......................................................................................48  
5.10  Storage and Accountability .................................................................................49  
5.11  Investigational Product Accountability at Study Site.......................................49  
5.11.1  Receipt and Disposition of Study Medication .............................................49  
5.11.2  Return of Study Medication  ..........................................................................49  
6. STUDY PROCEDURES  ..........................................................................................50  
6.1 Informed Consent  ................................................................................................50  
6.2 Demographics and Medical History  ...................................................................50  
6.3 Dispensing Investigational Product ....................................................................50  
6.4 Appropriateness of Measurements  .....................................................................51  
PG324 Ophthalmic Solution   
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 32 of 123  
   
 6.5 Efficacy Assessments  ...........................................................................................51  
6.5.1  Specification of the Efficacy Parameters  .....................................................51  
6.5.2  Method and Timing for Assessing Efficacy Parameters ............................52  
6.6 Assessment of Safety  ............................................................................................52  
6.7 Vital Signs  .............................................................................................................53  
6.7.1  Heart Rate .......................................................................................................53  
6.7.2  Blood Pressure  ................................................................................................53  
6.8 Clinical Laboratory Tests....................................................................................53  
6.8.1  Laboratory Parameters  .................................................................................53  
6.8.2  Pregnancy Testing  ..........................................................................................53  
6.9 Adverse Event Assessments and Ocular Safety  ................................................53  
6.9.1  Performing Adverse Events Assessments  ....................................................53  
6.9.2  Adverse Event Definitions  .............................................................................54  
6.9.3  Timing for Reporting of Adverse Events  .....................................................55  
6.9.4  Severity ............................................................................................................56  
6.9.5  Relationship  ....................................................................................................57  
6.9.6  Expectedness  ...................................................................................................57  
6.9.7  Clinical Significance .......................................................................................58  
6.9.8  Clinical Laboratory Adverse Events ............................................................58  
6.9.9  Serious Adverse Events (SAEs) or Serious Suspected Adverse 
Reactions  .........................................................................................................58  
6.9.9.1  Reporting Serious Adverse Events  .........................................................58  
6.9.10  Serious Unexpected Suspected Adverse Reactions (SUSARs)  ...................59  
6.9.10.1  Reporting Serious Unexpected Suspected Adverse Reactions  .............59  
6.9.11  Follow- up of Subjects after Adverse Events  ................................................60  
6.10  Comfort Test .........................................................................................................60  
6.11  Best Corrected Visual Acuity (BCVA)  ...............................................................60  
6.12  Pupil Size ...............................................................................................................60  
6.13  Biomicroscopy  ......................................................................................................60  
6.14  Gonioscopy/Pachymetry ......................................................................................60  
6.15  Visual Field Testing  .............................................................................................61  
6.16  Dilated Ophthalmoscopy  .....................................................................................61  
6.17  Removal of Subjects from the Study or Investigational Product ....................61  
6.17.1  Completed subject  ..........................................................................................61  
6.17.2  Non-completing subject  .................................................................................61  
6.17.3  Actions after Discontinuation .......................................................................62  
6.17.4  Discontinuation of the Entire Study  .............................................................62  
6.17.5  Completed study .............................................................................................62  
7. STUDY ACTIVITIES  ..............................................................................................63  
7.1 Study Visits  ...........................................................................................................63  
7.1.1  Visit 1 (Screening Visit)  .................................................................................63  
7.1.1.1  Evaluation of eye- drop instillation performance  ..................................63  
7.1.1.2  Washout ....................................................................................................64  
7.1.2  Visit 2 (Qualifying Visit #1, for 08:00 hours IOP measurement) ..............64  
7.1.3  Visit 3.0 (Qualifying Visit #2 [Day 1] for IOP measurement at 08:00 hours)  ..............................................................................................................65
 
PG324 Ophthalmic Solution   
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 34 of 123  
   
 9.5 Procedure for Accounting for Missing, U nused, or Spurious Data ................86  
9.6 Procedure for Reporting Deviations from the S tatistical Plan ........................86  
9.7 Data Listings .........................................................................................................86  
10. ADMINISTRATIVE CONSIDERATIONS  ...........................................................86  
10.1  GCP compliance  ...................................................................................................86  
10.2  Amendments to the Protocol  ...............................................................................87  
10.3  Investigators and Study Administrative Structure  ...........................................87  
10.4  Institutional Review Board (IRB) or Independent Ethics Committee 
(IEC) Approval.....................................................................................................87  
10.5  Ethical Conduct of the Study  ..............................................................................88  
10.6  Subject Information and Consent  ......................................................................88  
10.7  Subject Confidentiality  ........................................................................................88  
10.8  Study Monitoring  .................................................................................................89  
10.9  Case Report Forms and Study Records  .............................................................90  
10.10  Protocol Deviations ..............................................................................................91  
10.11  Access to Source Documentation  ........................................................................91  
10.12  Data Generation and Analysis ............................................................................92  
10.13  Retention of Data  .................................................................................................92  
10.14  Financial Disclosure  .............................................................................................92  
10.15  Publication and Disclosur e Policy  ......................................................................92  
11. REFERENCES  .........................................................................................................94  
11.1  Published References  ...........................................................................................94  
11.2  Internal References  ..............................................................................................95  
 
LIST  OF TABLES  
Table 1  Ocular Hypotensive Medication Washout Period ................................47  
 
LIST OF APPENDICES  
Appendix  1 Schedule of Visits and Examinations  .....................................................96  
  
Appendix  3 Market ed Product Information: Latanoprost Ophthalmic Solution, 
0.005%.....................................................................................................105  
Appendix  4 Sponsor’s Obligations ............................................................................115  
Appendix  5 Investigator’s Obligations  .....................................................................116  
Appendix  6 Declaration of Helsinki  ..........................................................................119  
Appendix  7 Sample SAS Code  ...................................................................................122  
 
 

PG324 Ophthalmic Solution   
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 35 of 123  
   
 LIST OF ABBREVIATIONS  AND DEFINITIONS OF T ERMS  
AE Adverse Event  
ALT  Argon laser trabeculoplasty  
BCVA  Best corrected visual acuity  
BOCF  Baseline observation carried forward  
BP Blood Pressure  
C Centigrade  
CFR  Code of Federal Regulations  
CRF  Case report form  
CRO  Contract research organization  
CV Curriculum vitae  
DHHS  Department of Health and Human Services  
EDC  Electronic data capture  
eCRF  electronic case report form  
ETDRS  Early Treatment of Diabetic Retinopathy Study  
F Fahrenheit  
FAX Facsimile communica tion 
FDA  Food and Drug Administration   
FDC  Fixed dose combination  
FP Prostaglandin F 2α 
GCP  Good clinical practice  
hCG  human chorionic gonadotropin  
hr Hour 
HR Heart rate  
ICF Informed consent form  
ICH International Conference on Harmonisation  
IEC Independent Ethics Committee  
IND Investigational New Drug  
IOP Intraocular Pressure  
IRB Institutional Review Board  
ITT Intent -To-Treat  
IWRS  Interactive Web -based response system  
kg Kilogram  
L Liter  
LASIK  Laser -assisted in -situ keratomileusis  
PG324 Ophthalmic Solution   
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 36 of 123  
   
 LOCF  Last observation carried forward  
logMAR  Logarithm of the minimum angle resolvable  
M.D.  Medical doctor  
MedDRA  Medical Dictionary for Regulatory Activities  
mg Milligram  
min Minute  
mL Millilite r 
mm Millimeter  
mmHg  Millimeters Mercury  
mOsmol  milliOsmoles  
OAG  Open angle glaucoma  
OHT  Ocular hypertension  
OTC  Over -the-counter 
OU Both eyes 
pH −log 10 [hydrogen ion concentration in moles/liter] 
PM Post meridian (ie, after noon) 
PP Per protocol 
PRK  Photorefractive keratectomy  
PT Preferred term  
QD Once daily  
ROCK  Rho kinase 
Rx Prescription  
SAE  Serious Adverse Event 
SITA  Swedish interactive threshold algorithm 
SLT Selective laser trabeculoplasty  
SOC  System/Organ/Class  
SSAR  Serious Suspected Adverse Reaction  
SUSAR  Suspected Unexpected Serious Adverse Reaction  
t1/2 Half-life 
US United States  
  
  
PG324 Ophthalmic Solution   
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 42 of 123  
   
 1. Must be 18 years of age or older 
2. Diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT) in both eyes 
(OAG in one eye and OHT in the fellow eye is acceptable)  
3. Unmedicated (post- washout) IOP > 20 mmHg and < 36 mmHg in both eyes at 2 
qualification visits at 08:00 hour, 2-7 days apart.  At the second qualification visit, have 
IOP > 17 mmHg and < 36 mmHg in both eyes at 10:00 and 16:00 hours.  Both eyes must 
qualify at all qualification visit time points .  Note: For purposes of determining 
eligibility  of subjects to be enrolled, any non- integral mean IOP number should not 
be rounded.    
4. Best c orrected visual acuity +1.0 logMAR or better by E TDRS in each eye 
(equivalent to  20/200 or better Snellen visual acuity in each eye) 
5. Be able and willing to give signed informed consent and follow study instructions 
4.3 Exclusion Criteria  
Individuals with the following characteristics  will be excluded from the study : 
Ophthalmic: 
1. Clinically significant ocular disease (eg corneal edema, uveitis, severe keratoconjunctiviti s sicca) which might interfere with interpretation of the study 
efficacy endpoints or with safety assessments, including subjects with glaucomatous damage so severe that washout of ocular hypotensive medications (if needed) for up to 1 month is not judged safe as it would put the subject  at risk for further vision loss  
2. Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure glaucoma, or narrow angles (i.e., Grade 2 or less [Shaffer scale]; extreme narrow angle with complete or partial closure) . Note: Previous laser peripheral 
iridotomy is NOT acceptable 
3. Intraocular pressure ≥ 36 mmHg (unmedicated) in either  eyes at any time point 
(individuals who are excluded for this criterion are not allowed to attempt requalification) , or use of more than two  ocular hypotensive medications within 
30 days of screening.  Note: fixed dose com bination medications, for the purpose of 
this exclusion criterion, count as one medication  
4. Known hypersensitivity to any component of the formulation, to latanoprost, or to topical anesthetic  
5. Previous glaucoma intraocular surgery , including SLT or ALT in e ither eye  
6. Refractive surgery in either eye (eg, radial keratotomy, PRK, LASIK, corneal cross -linking, etc.)  
PG324 Ophthalmic Solution   
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 43 of 123  
   
 7. Ocular trauma in either eye within the six months prior to screening, or ocular surgery 
or non- refractive laser treatment within the three months p rior to screening  
8. Recent or current evidence of ocular infection or inflammation in eithe r eye.  
Current  evidence of clinically significant blepharitis, keratitis or conjunctivitis.  
Additionally, current evidence or history  of herpes simplex or zoster ker atitis in 
either eye at screening is excluded .  
9. Used ocular medication in either eye of any kind within 30 days of screening and 
throughout the study, with the exception of a) ocular hypotensive medications (which  must be washed out according to the provided schedule), b) lid scrubs 
(which  may be used prior to, but not after screening), c) lubricating drops for dry eye 
(which may be used throughout the study), or d) non- cortico steroid  or non-
vasoconstrictor-containing allergy drops and allergy drops that do not have a redness reliever effect  as prescribed by the Investigator  
10. Mean central corneal thickness greater than 620 μm in either eye at screening  
11. Any abnormality preventing reliable applanation tonometry of either eye (eg, keratoconus, etc.) 
 
Systemic : 
12. Clinically significant abnormalities in laboratory tests at screening  
13. Clinically significant systemic disease (eg, uncontrolled diabetes, myasthenia gravis, hepatic, renal, endocrine or cardiovascular disorders) which might interfere with the study 
14. Participation in any investigational study within 6 0 days prior to screening  
15. Systemic  medication that could have a substantial effect on IOP within 30 days prior 
to screening, or anticipated during the study, including any cortico steroid -containing 
drug regardless of route of administration. 
16. Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control.  An adult woman is considered to be of childbearing potential unless she is one year post- menopausal or three 
months post- surgical sterilization.  All females of childbearing potential must have a 
negative urine pregnancy test result at the screening examination and must not intend to become pregnant during the study. 
PG324 Ophthalmic Solution   
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 44 of 123  
   
 4.4 Subject  Enrollment  
Enrollment numbers are higher in this study (230 subject s per arm) than s tatistically required 
for demonstrating efficacy at 90% power, accounting for an estimated 15% discontinuation 
rate over the course of the first 3  months of the study.  
5. STUDY TREATMENTS  
5.1 Description of Treatments  
5.1.1 Investigational Product 
• PG324 Ophthalmic Solution is a sterile, isotonic, buffered aqueous solution 
containing AR-13324 (0.02%), latanoprost (0.005%), boric acid, mannitol, w ater for 
injection, and preserved with benzalkonium chloride (0.02%).  The product 
formulation is adjusted to approximately pH 5.  
5.1.2 Comparator Products  
• Latanoprost Ophthalmic Solution, 0.005% is a sterile, isotonic, buffered aqueous solution of latanoprost with a pH of approximately 6.7 and an osmolality of approximately 267 mOsmol/kg. Each mL of Latanoprost Ophthalmic Solution, 0.005% contains 50 micrograms of latanoprost.  Benzalkonium chloride, 0.02% is added as a preservative. The inactive ingredients are sodium chloride, sodium dihydrogen phosphate monohydrate, disodium hydrogen phosphate anhydrous, and 
water for injection.  
• AR-13324 Ophthalmic Solution is a sterile, isotonic, buffered aqueous solution 
containing AR- 13324 (0.02%), boric acid, mannitol, w ater for injection, and 
preserved with benzalkonium chloride (0.015%).  The product formulation is adjusted 
to approximately pH 5.  
5.2 Treatments Administered   
There will be 3 treatments in this study:  
• PG324 (AR-13324, 0.02% and latanoprost, 0.005%) Ophthalmic Solution  
• AR-13324 Ophthalmic Solution, 0.02% 
• Latanoprost Ophthalmic Solution, 0.005%  
Subject s will be assigned according to  a computer -generated randomization list in a 1:1:1  
ratio to PG324 Ophthalmic Solution, AR-13324 Ophthalmic Solution, 0.02%, or Latanoprost 
Ophthalmic Solution, 0.005% (stratified by i nvestigative site  and by maximum baseline IOP  
[< 25 mmHg vs ≥ 25 mmHg] ).  Subject s will instill 1 drop of study drug into each eye, one 
time per day in the evening, at approximately 24 hour intervals ; all treatments will be OU.  
Doses will be self -administered by the study subjects.  For subject s deemed unable to 
PG324 Ophthalmic Solution   
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 45 of 123  
   
 self-administer the doses, a caregiver will be asked to administer the medication.  All subject s 
will administer study treatment for approximately 365 days.  
5.3 Selection and Timing of Dose for Each Subject  
The dose of PG324 selected for this study is based upon the positive outcomes seen for 
PG324 in the PG324-CS201 clinical study.  Each investigational product is being dosed QD OU (in the evening between 20:00 and 22:00 hours ) in this study to allow for estimated 
peak and trough levels of both AR-13324 and latanoprost to be present in ocular tissue at the observation times selected in the clinic for the following morning and the subsequent afternoon.  The treatment period is selected on the basis of nonclinical safety studies  and 
regulatory requirements for pivotal studies of ophthalmic glaucoma medications .  
5.4 Method of Assigning Subject s to Treatment Groups  
A randomization code for allocating the treatments will be prepared by an independent biostatistician who is not involved in the day- to-day conduct of the study.  Subject s will be 
randomized using an IWRS in a 1:1:1  ratio to receive PG324 Ophthalmic Solution, 
AR-13324 Ophthalmic Solution, 0.02%, or Latanoprost Ophthalmic Solution, 0.005%.   
5.5 Masking  
An independent person at the site not responsible for performing any of the study procedures is assigned to dispense, collect, and store investigational product while maintaining the masking of the study. 
Study related site personnel will be cautioned that any used or unused subject kits are not to 
be opened at the clinical site by the site staff involved in efficacy or safety  measurements.   
Treatment assignments will be masked to the Investigator, th e clinical study team 
(Sponsor, personnel involved in day to day study management, Data Managers, and 
Statisticians), and the subje cts prior to all subjects completing 3 months of treatment.  
Treatment assignment(s) will be unmasked and made available to the Investigator and the 
Sponsor ’s Medical Monitor during this period only in case of medical emergency or 
occurrence of adverse events that in the opinion of the investigator warrant unmasking.  In the absence of medical need, the randomization  code /treatment assignment(s)  will not be 
available to the above study personnel until after the study is completed and the database is 
locked.  
If the Investigator feels it is necessary to unmask a subject’s treatment assignment after an 
emergency situation, the Investigator should promptly contact the Sponsor ’s Medical 
Monitor or designee.  A decision will be made as to whether or not the treatment for the 
subject  should be unmasked, preferably after consultation with the Sponsor ’s Medical 
Monitor or designee .  The treatment assignment will be revealed on a subject- by-subject  
basis, thus leaving the masking on remaining subject s intact.   
PG324 Ophthalmic Solution   
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 46 of 123  
   
 In an emergency situation in which treatment of an adverse event requires immediate 
unmasking, and the Investigator is unable to promptly contact the Sponsor ’s Medical 
Monitor, the Investigator may unmask the treatment .  The masked portion of the kit label 
may b e revealed for the treatment assignment.  In the case of such unmasking in an 
emergency situation, the Investigator should contact the Sponsor immediately ther eafter and 
document the unmasking in writing, recording the date, time, and reason for unmasking the 
study drug treatment in the source documentation.  Individual unmasking by the Investigator will normally result in withdrawal of the subject from the study and should only be performed for the specific subject requiring unmasking in their treatment group.   
5.6 Concomitant Therapy  
Intermittent use of over-the- counter (OTC) artificial tear lubricant products is acceptable, 
with a minimum of 10 minutes between use of OTC products and study medication.  
However, concurrent therapy with any form of ocular hypotensive medications 
(prescription  or over-the-counter) is not allowed during the study.  Subjects who are not 
taking any concomitant disallowed ocular medication or who do not require washout of ocular hypotensive medication can return as soon as clinical chemistry and hematology 
results are received for Qualification Visit #1 (see Section  7.1.2 of this protocol for more 
details ). 
Disallowed concomitant ocular medications for enrolled subjects include: 
• Miotics  
• Epinephrine- related compounds  
• Carbonic anhydrase inhibitors (ocular or systemic)  
• α-adrenoceptor agonists  
• β- adrenoceptor antagonists  
• Muscarinic agonists ( eg, pilocarpine)  
• Prostaglandin analogues  other than that contained in the provided investigational 
product 
Systemic therapy with agents that could have an effect on IOP is to be consistent in dose, 
regimen and agent within the 30 days prior to screening and throughout the study , except for 
cortico steroid -containing drugs .  For example, a subject  can be treated with a systemic β-
adrenoceptor antagonist as long as the particular agent and its dose and regimen had been consistent for the 30 days prior to screening, and there is no reason to believe that alteration would be necessary at some point later during the study.  Subjects should be cautioned to avoid use of alcohol or the use of drugs such as marijuana during the study visit days.   
PG324 Ophthalmic Solution  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
Confidential  Page 47 of 123 Any corticosteroid -containing systemic drug is disallowed during the study regardless of 
route of administration.    
Contact lens wear  during the study is acceptable.  However, subject s must remove their 
contact lenses at least 30 minutes before instillation of study medication, and not place them 
in their eye(s) until 30 minutes after instillation.   
Use of all medications should be documented on the appropriate CRF.  Investigators are encouraged to contact the Sponsor for any questions regarding allowed medications.  Judgment of continued study participation by the subject , and inclusion of this subject ’s 
subsequent visits in the safety and efficacy analysis will be made by the Sponsor.   
All medications which the subject  has taken within 30 days prior to screening and during the 
study will be recorded in the CRF.  The name of the drug, dose, route of administration, 
duration of treatment and indication will be recorded for each medication.  For combination products ( eg, Contac
®), the brand name is required.  For non-combination products, the 
generic name is desired.  The use of routine ophthalmic diagnostic pharmaceutical agents (eg, fluorescein and local anesthetic) will be allowed, and individual documentation not 
required.  Any change in dosing parameters should also be recorded in the CRF.   
5.7 Restrictions  
5.7.1 Prior Therapy  
Individuals currently using ocular hypotensive medications must unde rgo a minimum 
washout period as specified 
in Table 1.   If washout is to be extended beyond 6 w eeks 
(42 days) for logi stical or other reasons, the Sponsor should be contacted.  If subjects need to 
washout of a hypotensive medication, they are not allowed to use a washout medication of 
shorter required washout time (including Azopt) than for the original hypotensive 
medication.  
Table  1 Ocular Hypotensive Medication Washout Period  
Medication c lass Minimum washout 
period  
Prostaglandins  4 weeks  
β-adrenoceptor antagonists  4 weeks  
Adrenergic agonists (including α-agonists such as brimonidine 
and apraclonidine)  2 weeks  
Muscarinic agonists ( eg, pilocarpine), Carbonic anhydrase 
inhibitors (topical or oral)  5 days  
Hughes 2005  
5.7.2 Fluid and Food Intake  
There are no general restrictions on fluid or food intake for subject s participating in this 
study.  
PG324 Ophthalmic Solution   
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 49 of 123  
   
 Ophthalmic Solution, 0.005% will be removed and replaced with an investigational label 
which will be similar in appearance for all treatment groups.   
Upon dispensing of a clinical trial material packer or kit to a subject, a portion of the kit label 
will be affixed to the designated study drug kit label log which will be part of the study files at the individual study site for this study. 
5.10 Storage and Accountability  
The investigational products should be stored refrigerated (2°C to 8°C/36°F to 46°F) until 
provided to the subject .  The subject  should be instructed that, once an investigational 
product bottle is opened, the product may  be kept refrigerated or at room temperature 
(up to 25°C/77°F) while continuing to store the bottle in the carton .  Do not freeze the 
product and protect from light.  Prior to dispensing to the subject , all investigational material 
must be stored in a secure location at the recommended long-term storage condition (2°C to  8°C) with s trictly limited access documented by signature of authorized persons who 
may dispense investigational product. Temporary temperature excursions up to 30°C are permissible.  
5.11 Investigational Product Accountability at Study Site    
5.11.1 Receipt and Disposition of St udy Medication  
Investigational product will be shipped to the Investigator’s site from a central depot.  A study staff member  at the Investigator’s site who is not involved in conducting any 
efficacy or safety procedures will verify study medication shipme nt records by comparing the 
shipping documentation accompanying the study medication to the study medication actually received at the Investigator’s site.  If a discrepancy is noted, the appropriate individual at the Sponsor or designee must be notified im mediately.  The responsible person for dispensing 
study medication  at the Investigator’s institution is the only site staff member that can 
distribute investigational product and also has sole responsibility to account for all returned used, partially used and unused bottles and kits of investigational products.  The investigational product(s) must not be used outside this protocol.  A Drug Accountability Log will be kept at the clinical site .  
5.11.2 Return of Study Medication  
When the study is completed or is terminated by the Sponsor, all study material including used and unused study medication kits will be returned to the Sponsor or their designee.  
All study medication accounting procedures must be completed before the study is 
considered to be concluded.  The responsible person at the  Investigator’s institution has  the 
sole responsibility to account for all used, partially used and unused bottles of investigational products.  This  site staff member at the Investigator’s institution will complete a study drug 
returns form or equivalent that will be signed by the Investigator or designee prior to returning the used and unused study medication kits and bottles to the Sponsor or their 
designee.  
PG324 Ophthalmic Solution   
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 51 of 123  
   
 Study staff responsible for dispensing investigational product will be listed on the Delegation 
of Responsibilities log.  When a subject meets all criteria for selection and has completed all screening assessments, the subject will be assigned to a treatment according to the interactive web-based response system (IWRS).  The responsible study staff will account for all used 
and unused investigation product packers and their kit contents by maintaining an investigational product accounta bility log.   
6.4 Appropriateness of Measurements  
The ophthalmic and systemic measures used in this study are consistent with standard of care.  In particular, intraocular pressure (IOP) as measured by Goldmann applanation 
tonometry, the primary efficacy asses sment in this study, is accepted worldwide as a standard 
for testing of pharmacologically  active agents intended to reduce IOP. 
6.5 Efficacy Assessments  
6.5.1 Specification of the Efficacy Parameters   
The primary efficacy outcome will be  the comparison of PG324 Opht halmic Solution relative 
to each of its active components, AR-13324, 0.02% and latanoprost, 0.005%, for the mean IOP within a treatment group at 08:00, 10:00, and 16:00 hrs at the Week 2, Week 6, and 
Month 3 study visits.   A description of the method for measuring IOP to be used in this study 
is contained in Appendix 2.  Study visits at Month 6, Month 9, and Month 12 will focus primarily on safety and will include measurement of IOP at 08:00, 10:00 and 16:00 hrs. 
Secondary efficacy  outcomes will include a summary of the following comparisons of 
PG324 Ophthalmic Solution relative to each of its active components (AR-13324, 0.02% and 
latanoprost, 0.005%) for: 
• Mean IOP within a treatment group at each post- treatment time point  
• Mean di urnal IOP within a treatment group at each post- treatment visit 
• Mean change from diurnally adjusted baseline IOP at each post -treatment time point  
• Mean change from baseline in diurnal IOP at each post -treatment visit  
• Mean percent change from diurnally adjusted baseline IOP at each post -treatment 
time point  
• Mean percent change from baseline in diurnal IOP at each post -treatment visit  
• Percentages of subjects achieving pre- specified mean, mean change, and percent 
mean change diurnal IOP levels  
Other secondary efficacy analyses will be carried out as described in the study Statistical Analysis Plan.  
PG324 Ophthalmic Solution   
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 54 of 123  
   
 All treatment-emergent adverse events occurring during the study, regardless of the 
assumption of causal relationship, must be documented on the respective CRF.  Adverse events  should be documented from the time the subject  receives the first dose of 
Investigational Product until the subject ’s participation in the study has been completed.  
If a subject  has an ongoing adverse event at the time of study completion, the ongoing 
adverse event must be followed-up and provided appropriate medical care until the event has 
resolved or stabilized.   
Documentation of adverse events/adverse reactions includes start date and stop date, severity, 
action(s) taken, seriousness and outcome.   
6.9.2 Adverse Event Definitions  
The following definitions of terms apply to this section: 
• Adverse event: any untoward medical occurrence associated with the use of a drug in 
humans, whether or not considered drug related.   
• Life-threatening adverse event or life- threatenin g suspected adverse reaction: an 
adverse event or suspected adverse reaction is considered “life -threatening” if, in the 
view of either the Investigator or Sponsor, its occurrence places the subject or subject  
at immediate risk of death.  It does not include an adverse event or suspected adverse 
reaction that, had it occurred in a more severe form, might have caused death.   
• Serious adverse event (SAE) or serious suspected adverse reaction  (SSAR) :  an 
adverse event or suspected adverse reaction is  considered ‘‘serious’’ if, in the view of 
either the Investigator or Sponsor, it results in any of the following outcomes: Death, a life -threatening or sight- threatening adverse event, in subject hospitalization or 
prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect.  Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based 
upon appropriate medical judgment, they may jeopardize the subject  and may require 
medical or surgical intervention to prevent one of the outcomes listed in this definition.  Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in subject  hospitalization, or the development of drug 
dependency or drug abuse. 
• Suspected adverse reaction: any adverse event for which there is a reasonable 
possibility that the drug caused the adverse event.  For the purposes of IND safety reporting, ‘‘reasonable possibility’’ means there is evidence to suggest a causal relationship between the drug and the adverse event.  Suspected adverse reaction implies a lesser degree of certainty about causality than adverse reaction, which means any adverse event caused by a drug.   
PG324 Ophthalmic Solution   
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 55 of 123  
   
 • Unexpected adverse event or unexpected suspected adverse reaction:  an adverse 
event or suspected adverse reaction is considered ‘‘unexpected’’ if it is not listed in 
the Investigator’s Brochure  or is not listed at the specificity or severity that has been 
observed; or, if an Investigator’s Brochure is not required or available, is not consistent with the  risk information described in the general investigational plan or 
elsewhere in the current application, as amended.  For example, under this definition, hepatic necrosis would be unexpected (by virtue of greater severity) if the Investigator’s Brochure  referred only to elevated hepatic enzymes or hepatitis.  
Similarly, cerebral thromboembolism and cerebral vasculitis would be unexpected (by virtue of greater specificity) if the Investigator’s Brochure listed only cerebral 
vascular accidents.  “Unexpected,” as used in this definition, also refers to adverse events or suspected adverse reactions that are mentioned in the Investigator’s Brochure  as occurring with a class of drugs or as anticipated from the 
pharmacological properties of the drug, but are not specifically mentioned as occurring with the particular drug under investigation. 
Note: Any medical condition present prior to administration of the masked study medication which remains unchanged or improved should not be recorded as an adverse event at subsequent visits. 
Note: If an event occurs during the washout period, prior to subject  enrollment and the 
commencement of study medication, it should be recorded as part of the Medical History and 
not as an adverse event.  As noted in Section  7.1.2, any change in their Visit 1 (screening)  
health status should be recorded on the Medical History page of the CRF (eg, the subject has been diagnosed with cancer).  
Note: In the present study, Investigators are asked to us e the verbatim term  “conjunctival 
hyperemia” on the study AE form to describe observations of conjunctival redness  if the 
ocular redness  observation is increased from Visit 1 (S creening) observations .  Investigators 
are also asked to note all observations of conjunctival hyperemia on the biomicroscopy CRF as well as on the study AE form. 
6.9.3 Timing  for Reporting of Adverse Events  
The AEs occurring during the study must be documented, regardless of the assumption of a causal relationship.  AEs should be document ed from the time the subject  receives the first 
dose of investigational product until subject  participation in th e study has been completed.  
If a subject  has one or more ongoing AEs at the time of study completion, the subject  must 
be followed and provided appropriate medical care until the sign(s) and/or symptoms(s) of the AE have remitted or stabilized in the opinion of the Investigator. 
When recording an AE, the following information should be provided on the study AE CRF: 1. Action Taken with Study Drug:  
• None 
PG324 Ophthalmic Solution   
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 56 of 123  
   
 • Investigational Product Discontinued 
• Investigational Product Interrupted 
2. Other Action Taken:  
• None 
• Non-Drug Therapy  
• New OTC or Rx Drug Added  
• Hospitalized less than 24 hours 
• Hospitalized greater than or equal to 24 hours 
3. Outcome of an adverse event is to be coded as: 
• Fatal  
• Not Recovered/Not Resolved 
• Recovered/Resolved  
• Recovered/Resolved with sequelae  
• Recovering/Resolving 
• Unknown/Lost to follow-up 
6.9.4 Severity  
Severity of an adverse event is defined as a qualitative assessment of the level of discomfort 
or the degree of intensity of an adverse event as determined by the Investigator or reported to 
him/her by the subject .  The assessment of severity is made irrespective of study medication 
relationship or seriousness of the event and should be evaluated according to the following scale:  
• 1 = Mild: present and noticeable, but not distressing, and no disruption of normal 
daily activities  
• 2 = Moderate:  bothersome, discomfort sufficient to possibly reduce or affect normal 
daily activity  
• 3 = Severe: incapacitating,  with inability to work or perform normal daily activity  
PG324 Ophthalmic Solution  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
Confidential  Page 57 of 123 A change in severity for a reported AE will require a stop date for the previous severity and a 
new start and stop date for the new severity.  For example, a change in severity may go from mild to se vere, or from severe to moderate.  In either case, the start and stop dates should be 
recorded.   
Please note: a severe AE is not the same as a serious AE.  Seriousness of an AE (NOT severity) serves as a guide for defining regulatory reporting obligations (see Section  6.9.9 for 
further information on serious AEs [SAEs]) . 
6.9.5 Relationship  
The study medication relationship for each adverse event/adverse reaction should be determined by the Invest igator using these explanations: 
•Not Related : The event is clearly related to other factors such as subject ’s clinical
condition, therapeutic interventions, concomitant disease or therapy administered tothe subject  and does not follow a known response pattern to the product.
•Unlikely Related : The event is most probably caused by other etiologies such as
participant’s underlying condition, therapeutic intervention, or concomitant therapy;or the delay between administration and the onset of the AE is incompatible with acausal relationship. The refore, there is not a reasonable possibility that the AE was
caused by the study medication.
•Possibly Related :  The event follows a reasonable, temporal sequence from the time
of study medication administration and/or follows a known response pattern to t he
study medication, but could have been produced by other factors such as the subject ’s
clinical state, therapeutic interventions or concomitant therapy administered to thesubject .
•Related :  The event follows a reasonable, temporal sequence from the time of study
medication administration and/or follows a known response pattern to the studymedication and cannot be reasonably explained by other factors such as subject ’s
clinical state, therapeutic interventions or concomitant therapy administered to thesubject , and either occurs immediately following study medication administration, or
improves on stopping the study medication, or reappears on repeat exposure, or thereis a positive reaction at the application site.
6.9.6 Expectedness  
For AR -13324, the most frequently reported AE in 3 Phase 2 studies ( AR-13324-CS201, 
AR-13324-CS202, and  PG324-CS201) has been conjunctival hyperemia.  Other AEs seen in 
greater frequency with AR -13324 than in active control treatment arms in these studies 
include instillation site erythema or pain, conjunctival hemorrhage, blurred vision, eye 
irritation, increased lacrimation, and foreign body sensation. 
PG324 Ophthalmic Solution   
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 58 of 123  
   
 The most common AEs seen with Latanoprost Ophthalmic Solution, 0.005% in clinical trials 
as reported in the latanoprost prescribin g information ( Appendix 3) include conjunctival 
hyperemia, eyelash changes, increased  iris pigmentation, eyelid skin darkening, macular 
edema (including cystoid macular edema), and intraocular inflammation (iritis/uveitis).  
An AE or suspected adverse reaction is considered “unexpected” if it is not listed in the 
Investigator’s Brochure  or is not listed at the specificity or severity that has been observed.  
“Unexpected,” as used in this definition, also refers to adverse events or suspected adverse reactions that are mentioned in the Investigator’s Brochure  as occurring with this class of 
drugs or as anticipated from the pharmacological properties of AR-13324 or latanoprost, and are not specifically mentioned as occurring with the i nvestigational product.  The AEs that 
are both unexpected and serious should be reported in an expedited fashion to the Sponsor (see Section  6.9.10 for further details).  
6.9.7 Clinical Significance  
Determination of whether a finding is clinically significant will be made by the Principal Investigator or the Sub-Investigator and will be documented on the CRF . 
6.9.8 Clinical Laboratory Adverse Events 
Clinical laboratory values (other than pregnancy tests results) that are noted as abnormal and clinically significant at study exit and that are changes from Visit 1 (screening) values will be document ed as AEs . 
6.9.9 Serious Adverse Events (SAEs) or Serious Suspected Adverse Reaction s  
6.9.9.1 Reporting Serious Adverse Events 
An investigator must immediately r eport any SAE or SSAR  (see Section  6.9.2 for 
definitions) to the Sponsor or Rho Product Safety, the Sponsor CRO representative, whether 
or not the SAE or SSAR is considered drug-related, including those listed in the protocol or 
Investigator’s Brochure .  The investigator report must include an assessment of whether there 
is a reasonable possibility that the drug caused the event.  The Investigator must report any SAE or SSAR that occurs during the study for a subject  or any SAE or SSAR tha t occurs 
within 4 weeks (ie, 30 days) after the last administration of IP. Study endpoints that are 
serious adverse events ( eg, all-cause mortality) must be reported in accordance with the 
protocol unless there is evidence suggesting a causal relationship between the drug and the event ( eg, death from anaphylaxis).  In that case, the Investigator must immediately report 
the event to the Sponsor.  The investigator must record non-serious adverse events and report them to the Sponsor according to the timetable for reporting specified in the protocol.  In case of incomplete information, the Investigator must provide follow-up information as soon as possible, again using the SAE report form.   
In addition, in the case of immediately life -threatening A Es or AEs with fatal outcome, or 
adverse events that are serious, unexpected (ie, not in the Investigator’s Brochure ) and 
PG324 Ophthalmic Solution   
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 60 of 123  
   
 6.9.11 Follow- up of Subjects after Adverse Events  
If an adverse event/adverse reaction occurs, the Investigator will institute support and/or 
treatment as deemed appropriate.  If a non -serious adverse event/adverse reaction  is 
unresolved at the time of the last visit, efforts will be made to follow up until the adverse event/adverse reaction  is resolved or stabilized, the subject  is lost to follow -up, or there is 
other resolution to the event.  
6.10 Comfort Test  
Individuals will be asked “Did you experience any discomfort when placing the drops in your 
eyes?”  This will refer to the study medication use the previous evening.  The response will be scored as None, Mild, Moderate or Severe.  
6.11 Best Corrected Visual Acuity  (BCVA)  
Best corrected visual acuity (BCVA ) will be taken at visits as a measure of ocular function  
and will be measured at screening and frequently throughout the study. Visual acuity will be measured using ETDRS charts or their equivalents.  Accepted charts are those designed according to the principles described by Ferris and coworkers  (Ferris 1982 ) and supported by 
the guidelines from the Eye Care Technology Forum ( Ferris 1996).  
See Appendix 2 for details of the procedures to be followed when determining BCVA .   
6.12 Pupil Size 
Pupil size will be measured prior to dilation with a ruler to the nearest 0.5 mm in ambient 
room light.  
6.13 Biomicroscopy  
Biomicroscopic examina tion of the eyelids, conjunctiva, cornea, anterior chamber, lens, iris, 
and pupil of both lenses will be carried out at every study visit for both eyes of subjects.  Normal or abnormal status of these ocular tissues will be graded as described in Appendix 2.  
6.14 Gonioscopy/Pachymetry 
Gonioscopy will be used to confirm the iridocorneal angle is open and to what extent. Eligible subjects must have an angle grading of 3 or 4 (Shaffer grading scale: Kolker 1976) for participation in the study.  Pachymetry will be used to measure the thickness of the central cornea.  Both of these assessments will be done in order to determ ine the eligibility of 
a subject to be enrolled in this study.  Further information on these procedures is found in Appendix 2. 
PG324 Ophthalmic Solution   
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 62 of 123  
   
 • Adverse Events (adverse events including, in the opinion of the investigator, 
clinically relevant laboratory abnormalities and intercurrent diseases reported by the 
subject or observed by the investigator with documentation on the CRF)   
• Withdrawal of consent  
• Non-compliance (eg, use of disallowed medication and/or non- adherence to 
scheduled follow-up visits) 
• Lost to follow- up 
• Lack of efficacy  (as demonstrated by IOP measurements  and investigator decision 
that there is a risk of additional glaucomatous damage if the subject continues in the study)   
• Disallowed concurrent medication  
• Investigator decision 
• Protocol violation 
• Death  
• Other 
6.17.3 Actions after Discontinuation 
All subjects who discontinue Investigational Product due to a report of an AE must be followed-up and provided appropriate medical care until their signs and symptoms have remitted or stabilized or until clinically significant abnormal laboratory findings have returned to acceptable or pre- study limits.  
For the subject who chooses to withdraw consent or who is discontinued for non- complian ce, 
every possible effort should be made by the Investi gator to assure there is an exit  visit that 
includes all examinations listed for Visit 9.0 (Day 365) and dilated ophthalmoscopy.   
6.17.4 Discontinuation of the Entire Study  
The entire study may be discontinued at a given site (by the Investigator or the Sponsor) or for all sites (by the Sponsor).  Prompt, written notice of reasonable cause to all  other relevant 
parties  (Sponsor or Investigator) is required.  Prompt notice to t he IRB /IEC  and to regulatory 
authorities is also required. 
6.17.5 Completed study  
The study is completed when the planned enrollment has been completed, and all enrolled 
subjects have completed the study.  The Sponsor or  their designated representative(s) will be 
PG324 Ophthalmic Solution   
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 63 of 123  
   
 in communication with investigational sites regarding completion of enrollment and the in-
life portion of  the study.   
7. STUDY ACTIVITIES  
The schedule of s tudy visits and procedures is  shown  in Appendix 1.  
7.1 Study Visits  
7.1.1 Visit 1 (Screening Visit)  
This visit may occur at any time of the day.  Individuals who are potential subject s will arrive 
at the Investigator’s office at any time point during the day.   
A member o f the Investigator’s staff will interview the individual as to their qualifications for 
participation in the study.  Individuals will be asked to review the informed consent, discuss 
issues as needed, and to sign the form.  Significant  medical and ophthalm ic history including 
systemic and ocular medication use will be taken, and demographic measures recorded  
(see Section  6.2).  An examination will be conducted, including measurement of heart rate 
and blood pressure, a urine preg nancy test (for females of childbearing potential), collection 
of a blood sample for clinical laboratory assessments, and an ophthalmic examination to include symptoms, best corrected visual acuity (BCVA), intraocular pressure (before pupil dilation), biom icroscopy, gonioscopy, central corneal thickness by ultrasound pachymetry, 
visual field testing, and dilated ophthalmoscopy.  Gonioscopy and visual fields may be taken 
up to three months (ie, within 90 days) prior to randomization.  If assessment of visual  fields 
requires dilation due to subject small pupils, visual field testing should not take place within 
48 hours of Visit 2 ( Qualification Visit #1).  
Pachymetry must be taken at screening Visit 1 or within one week of Visit 1 .  The results of 
blood work should be reviewed after this study visit in order to determine eligibility of the subject  prior to undertaking the examination at Visit 2 (Q ualification Visit #1).  For subject s 
who are unable or unwilling to have blood drawn for clinical labs at Visit 1 (screening), the 
blood sample may be drawn at Visit 2 (Qualification Visit #1) so long as the results of the clinical labs are available for that subject  prior to Visit 3 (Qualification Visit #2).  
All females of childbearing potential must have a negative urine pregnancy test result at the screening examination and must not intend to become pregnant during the study. 
The Investigator will evaluate the results of these examinations for possible enrollment of the 
individual into the study.  All individuals wh o are qualified for enrollment at this study visit 
should undergo a washout period (if needed)  as noted in Section  5.7.1 and will be asked to 
return for Visit 2 (Qualification Visit #1) .  
7.1.1.1 Evaluation of eye-drop instillation per formance  
Subject s (or a legally authorized representative for subjects deemed unable to 
self-administer) will be provided a bottle of commercially available, multi-dose, 
PG324 Ophthalmic Solution   
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 64 of 123  
   
 non-medicated artificial tears in a room with access to water and soap.  Medication in stiller 
will be asked to instill a drop of the artificial tear in each eye under the observation of a 
member of the investigator’s staff.  The staff will observe the subject or representative to 
assure that they instill one drop of the artificial tear into  each eye, without touching the tip of 
the bottle to their eye or face ( Stone 2009 ).  The staff member may work with the individual 
to improve their delivery technique to meet this standard.  If the instiller (or  representative) 
cannot demonstrate proper delivery of the eye drop, or if staff member feels that the individual will be unable to do so consistently, then the subject  will be excluded from further 
study participation.   
7.1.1.2 Washout 
As noted in Section 5.7.1., a washout period is required for individuals currently using ocular 
hypotensive medications.  The Investigator is encouraged to have interim visits during the washout period for intraocular pressure measurement for individuals to  whom the washout 
period may be a risk for further glaucomatous progression.  
7.1.2 Visit 2 (Qualifying Visit #1, for 08:00 hours IOP measurement) 
After the washout, if required, individuals will return to the Investigator’s office in the early 
morning.  For individuals not requiring washout of ocular hypotensive medication, this visit should take place at least one day and no later than approximately 28 days subsequent to the 
screening visit.  The subject  will be questioned regarding any changes in their health or 
concomitant medication use.  Any change in the individual’s Visit 1  health status or use of 
concomitant medications should be recorded on the Medical History page of the CRF 
(eg, the subject  has been diagnosed with cancer).  Inclusion/exclusion criteria will be 
reviewed again for the qualified individual, and the subject ’s heart rate and blood pressure 
will be measured .  Results of the clinical laboratory tests from Visit 1 need to be available, 
and reviewed by the Investigator. For subjects who were unable or unwilling to have blood drawn for clinical labs at Visit 1, the blood sample may be drawn at Visit 2 (Qualification  Visit #1) so long as the results of the clinical labs are available for that subject 
prior to Visit 3 (Qualification Visit #2).  
The following procedures then will be perform ed: 
• Symptomatology: Individuals will be asked “How are you feeling?”  
• Best c orrected visual acuity  
• A non-dilated eye examination will be performed, including IOP and biomicroscopy 
o IOP must be measured within 30 minutes of the nominal time (ie, 07:30 to 
08:30 hours) 
o IOP measurements:  Unmedicated (post- washout) IOP > 20 mmHg and  
< 36 mmHg in both eyes at this qualification visit at 08:00 hour is required. This 
is the first of four qualifying IOPs for randomization .  Individuals who do 
PG324 Ophthalmic Solution   
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 65 of 123  
   
 NOT  meet this requireme nt may return for up to 2 additional (unscheduled) 
qualification visits within 1 week of failing this qualification visit.  Individuals 
returning at an unscheduled visit within 1 week are required to only re- measure 
IOP in both eyes.  Individuals who screen fail due to IOP being ≥ 36 mmHg in 
either eye at this study visit or at an unscheduled visit within 1 week of the 
original visit MAY NOT  return for additional qualification visits and ar e to be 
exited from the study.  
Qualified individuals who have met al l criteria at this study visit will be scheduled to return 
2-7 days later for the second qualification visit.   
7.1.3 Visit 3. 0 (Qualifying Visit #2 [Day 1] for IOP measurement at 08:00 hours) 
Within 2 to 7 days after Visit 2, individuals will return to the Inve stigator’s office for the next 
08:00 hour IOP measurement.  The results of the clini cal laboratory tests from Visit 1 or 
Visit 2 need to be available, and reviewed by the Investigator.  In order for the individual to 
be enrolled at a subsequent visit, the tests CANNOT be indicative of any clinically 
significant disease in the opinion of the Investigator.  The subject  will be questioned 
regarding any changes in their health or concomitant medication use.  Any change in the individual’s health relative to the ir Visit 1 (screening)  or Visit 2 health status and 
concomitant medication use should be recorded on the Medic al History page of the CRF 
(eg, the subject  has been diagnosed with cancer).  Inclusion/exclusion criteria will be 
reviewed again for the qualifie d individual.   
The following procedures will be performed: 
• Symptomatology: Individuals will be asked “How are you feeling?” 
• Heart rate and blood pressure 
• Best corrected visual acuity  
• A non-dilated eye examination will be performed, including pupil size, IOP and 
biomicroscopy   
o IOP must be measured within 30 minutes of the nominal time (ie, 07:30 to 
08:30 hours) 
o IOP measurements:  Unmedicated (post- washout) IOP > 20 mmHg and 
< 36 mmHg in both eyes at this study visit at 08:00 hour is required.  This is the 
second of four qualifying IOPs for randomization .   
Qualified individuals will continue with the measurements of IOP at 10:00 hours and 16:00 hours on the day of this study visit.  Individuals who do NOT meet the above IOP  
requirement may return for up to 2 additional (unscheduled) qualification visits within 1 week of failing this qualification visit.  Individuals returning at an unscheduled visit within 
1 week are required to only re-measure IOP in both eyes.  Upon return for an unscheduled 
PG324 Ophthalmic Solution   
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 66 of 123  
   
 qualification visit, such individuals’ IOP measurements would need to qualify at each of 
08:00, 10:00 and 16:00 hours.  Individuals who screen fail due to IOP being ≥ 36 mmHg  in 
either eye (exclusion criterion) at any of these time points  at this study visit or at an 
unscheduled visit within 1 week of the original visit MAY NOT return for additional qualification visits  and are to be exited from the study.  
Individuals are allowed to leave the I nvestigator’s office on the day of this study visit 
between assessments, and eat and drink with no restrictions .  However, individuals are not to 
consume alcohol or engage in strenuous exercise.  
7.1.4 Visit 3. 1 (Day 1, for IOP measurement at 10:00 hours) 
Inclusion/exclusion criteria will be reviewed again for the q ualified individual.  
Qualified  individuals will be examined.  Each examination will include:  
• Symptomatology: Individuals will be asked “How are you feeling?” 
• A non-dilated eye examination will be performed, including IOP and biomicroscopy  
o IOP must be measured within 30 minutes of the nominal time (ie, 09:30 to 
10:30 hours)  
At this and any other in -office visit, any subject  complaining of visual function issues 
will have visual function assessed as judged appropriate by the Investigator.   
For further participation  in the study, unmedicated IOP at this time (10:00 hours , Day  1) 
must be > 17 mmHg  and <  36  mm Hg in both eyes.  This is the third of four qualifying 
IOPs for randomization.   Qualified individuals will continue with the qualification visit.  Individuals who do NOT 
meet this requirement may return for up to 2 additional unscheduled qualification visits within 1 week of failing this qualification visit.  Individuals returning at an unscheduled visit 
within 1 week are required to only re-measure IOP in both eyes.  Upon return, such individuals would need to qualify at 08:00, 10:00 and 16:00 hours.  Individuals who screen fail due to IOP being ≥ 36  mmHg  in either eye  (exclusion criterion) at any of these time 
points at this study visit or at an unscheduled visit within 1 week of the original visit MAY NOT  return for additional qualification visits  and are to be exited from the study.  
Individuals are allowed to leave the I nvestigator’s office on the day of this study visit 
between assessments, and eat and drink without restrictions.  However, individuals are not to 
consume alcohol or engage in strenuous exercise. 
7.1.5 Visit 3. 2 (Day 1, for IOP measurement at 16:00 hours) 
Inclusion/exclusion criteria will be reviewed again for the qualified individual.   
Qualified individuals will be examined.  Each examination will include:  
PG324 Ophthalmic Solution   
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 67 of 123  
   
 • Symptomatology: Individuals will be asked “How are you feeling?” 
• A non-dilated eye examination will be performed, including IOP and biomicroscopy 
o IOP must be measured within 30 minutes of the nominal time (ie, 15 :30 to 
16:30 hours) 
For further participation  in the study, unmedicated IOP for a subject must be > 17 mmHg  and 
< 36 mmHg in both eyes at this time (16:00 hours, Day 1).  This is the fourth of four 
qualifying IOPs for randomization .   
Individuals who do NO T meet this requirement may return for up to 2 additional 
unscheduled qualification visits within 1 week of failing the first qualification visit.  
Individuals returning at an unscheduled visit within 1 week are required to only re- measure 
IOP in both eyes.  Upon return, such individuals would need to qualify at 08:00, 10:00 and 16:00 hours.  Individuals who screen fail due to IOP being ≥ 36 mmHg  in either eye  
(exclusion  criterion) at any of these time points at this study visit or at an unscheduled visit 
within 1 week of the original visit MAY NOT return for additional qualification visits  and 
are to be exited from the study . 
As noted in Section  4.2, subject s must  qual ify in both eyes based upon IOP and ocular 
history.  For a subject who qualifies, the study eye will be the eye with the higher IOP  at 
08:00 hours on Visit 3.  If both eyes have the same IOP at 08:00 hours on Visit 3, then the 
right eye will be the study eye .  In each subject , BOTH eyes will be treated.   
At this point, eligible subject s will be enrolled and assigned to an investigational product 
through an IWRS system according to a computer -generated randomization list .  The first kit 
removed from an investigational product packer assigned through the IWRS system to the 
eligible subject  will be dispensed unopened to the subject , along with written storage 
instructions.   
Subject s will be :  
• Instructed to self -administer their masked medication at home between 20:00-22:00 
hours (8  PM and 10 PM ) beginning with the evening dose on that day   
• Instructed to return to the office with their study medication at Week 2 (Day 15)   
7.1.6 Visit 4.0 (Week 2 [Day 15], for IOP measurement at 08:00 hours) 
Subject s will return to the Investigator’s office  with their study medication .  The subject  will 
be questioned about any missed doses and any changes in their health or concomitant 
medication use.  
Subje cts will be examined and each examination will include: 
• Heart rate and blood pressure 
PG324 Ophthalmic Solution   
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 68 of 123  
   
 • Symptomatology:  Individuals will be asked “How are you feeling”?  
• Recording of any AEs  
• Comfort Test: Individuals will be asked “Did you experience any discomfort when 
placing the drops in your eyes?” 
• Best corrected visual  acuity  
• A non- dilated eye examination will be performed, including IOP measurements and 
biomicroscopy  
o IOP must be measured within 30 minutes of the nominal time (ie, 0 7:30 to 
08:30 hours)  
• Collect study medication from the subject . 
After randomization, any new or worsening of symptoms beyond those collected at the 
baseline visit are to be entered as adverse events.  
Subjects are allowed to leave the Investigator’s office on the day of this study visit betw een 
assessments, and eat and drink without restrictions.  However, individuals are not to consume alcohol or engage in strenuous exercise. 
7.1.7 Visit 4.1 (Week 2 [Day 15], for IOP measurement at 10:00 hours) 
Subject s will be examined and each examination will include: 
• Symptomatology: Individuals will be asked “How are you feeling?” 
• A non-dilated eye examination will be performed, including IOP and biomicroscopy 
o IOP must be measured within 30 minutes of the nominal time (ie, 09:30 to 
10:30 hours) 
Subjects are allowed to leave the Investigator’s office on the day of this study visit between 
assessments, and eat and drink without restrictions.  However, individuals are not to consume alcohol or engage in strenuous exercise. 
7.1.8 Visit 4.2 (Week 2 [Day 15], for IOP measurement at 16:00 hours) 
Subject s will be examined and each examination will include: 
• Symptomatology: Individuals will be asked “How are you feeling?” 
• A non-dilated eye examination will be performed, including IOP and biomicroscopy 
PG324 Ophthalmic Solution   
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 69 of 123  
   
 o IOP must be measured within  30 minutes of the nominal time (ie, 15:30 to 
16:30 hours)  
Subject s will be: 
• Instructed to continue to self-administer their masked medication at home between 
20:00 - 22:00 hours (8  PM and 10 PM , beginning with the evening dose on that day).   
• They also w ill be instructed to return to the office with their study medication at 
Week 6 (Day 43)  
One subject  kit from the originally assigned subject packer will be dispensed to the subject , 
along with storage instructions. 
7.1.9 Visit  5.0 (Week 6 [Day 43] , for IOP mea surement at 08:00 hours) 
Subject s will return to the Investigator’s office  with their study medication .  The subject  will 
be questioned about any missed doses and any changes in their health or concomitant 
medication use.  
Subjects will be examined and each examination will include: 
• Heart rate and blood pressure 
• Symptomatology: Individuals will be asked “How are you feeling?” 
• Recording of any AEs  
• Comfort Test: Individuals will be asked “Did you experience any discomfort when 
placing the drops in your eyes?” 
• Best corrected visual acuity  
• A non- dilated eye examination will be performed, including IOP measurements and 
biomicroscopy  
o IOP must be measured within 30 minutes of the nominal time (ie, 07:30 to 
08:30 hours) 
• Collect study medication from the subject  
After randomization, any new or worsening of symptoms beyond those collected at the 
baseline visit are to be entered as adverse events.  
Subjects are allowed to leave the Investigator’s office on the day of this study visit between 
assessments, and eat and drink without restrictions.  However, individuals are not to consume alcohol or engage in strenuous exercise. 
PG324 Ophthalmic Solution   
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 70 of 123  
   
 7.1.10 Visit 5.1 (Week 6 [Day 43], for IOP measurement at 10:00 hours) 
Subject s will be examined and each examination will include: 
• Symptomatology: Individ uals will be asked “How are you feeling?” 
• A non-dilated eye examination will be performed, including IOP and biomicroscopy 
o IOP must be measured within 30 minutes of the nominal time (ie, 09:30 to 
10:30 hours)  
Subjects are allowed to leave the Investigator ’s office  on the day of this study visit between 
assessments, and eat and drink without restrictions.  However, individuals are not to consume alcohol or engage in strenuous exercise. 
7.1.11 Visit 5.2 (Week 6 [Day 43], for IOP measurement at 16:00 hours) 
Subject s will be examined and each examination will include: 
• Symptomatology: Individuals will be asked “How are you feeling?” 
• A non-dilated eye examination will be performed, including IOP and biomicroscopy 
o IOP must be measured within 30 minutes of the nominal time (ie, 15:30 to 
16:30 hours) 
Subject s will be: 
• Instructed to continue to self-administer their masked medication at home between 
20:00 - 22:00 hours (8  PM and 10 PM , beginning with the evening dose on that day)   
• Instructed to return to the office with their study medication on Month 3 (Day 90)   
• Two subject  kits from the originally assigned subject  packer for this subject will be 
dispensed to the subject , along with storage instructions 
7.1.12 Visit 6.0 (Month 3 [Day 90], for IOP measurement at 08:00 hours) 
Subje cts will return to the Investigator’s office  with their study medication .  The subject  will 
be questioned about any missed doses and any changes in their health or concomitant medication use.  
Subject s will be examined and each examination will include: 
• Heart rate and blood pressure 
• Urine Pregnancy Test (female subject s of childbearing potential; as applicable)  
PG324 Ophthalmic Solution  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
Confidential  Page 71 of 123 •Blood samples will be taken for clinical chemistry  and hematology (see Appendix 1). 
Note t
hat these samples may b e taken at any time of  the day
•Symptomat
ology: Individuals will be asked “How are you feeling ?”
•Recording of any AEs
•Comfort Test: Individuals will be asked “Did you experience any discomfort when
placing the drops in your eyes?”
•Best corrected visual acuity
•A non-dilated eye examination will be performed, including pupil size, IOP
measurements and biomicroscopy
oIOP must be measured within 30 minutes of the nominal time (ie, 07:30 to
08:30 hours)
•Pachymetry at the study visit or within one week of the study vi sit
•Visual fields (Note: may be assessed up to one week prior to this visit, or later in themorning or afternoon of this series of Day 90 visits so long as it occurs after IOPmeasurement at that visit). See  Appendix 2 for furthe r details when dilation is
required due to subject small pupils
•Collect  study medication from the subject .
After randomization, any new or worsening of symptoms beyond those collected at baseline are to be entered as adverse events.  
Subjects are allowed to  leave the Investigator’s office on the day of this study visit between 
assessments, and eat and drink without restrictions.  However, individuals are not to consume alcohol or engage in strenuous exercise. 
7.1.13 Visit 6.1 (Month 3 [Day 90] , for IOP measurement at 10:00 hours) 
Subject s will be examined and each examination will include: 
•Symptomatology: Individuals will be asked “How are you feeling?”
•A non-dilated eye examination will be performed, including IOP and biomicroscopy
oIOP must be measured within 30 minutes of the nominal time (ie, 09:30 to
10:30 hours)
PG324 Ophthalmic Solution  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
Confidential  Page 72 of 123 Subjects are allowed to leave the Investigator’s office on the day of this study visit between 
assessments, and eat and drink without restrictions.  However, individuals are not to consume 
alcohol or engage in strenuous exercise. 
7.1.14 Visit 6.2 (Month 3 [Day 90], for IOP measurement at 16:00 hours) 
Subject s will be examined and each examination will include: 
•Symptomatology: Individuals will be asked “How are you feeling?”
•A non- dilated eye examination will be performed, including IOP and biomicroscopy
oIOP must be measured within 30 minutes of the nominal time (ie, 15:30 to
16:30 hours)
•A dilated ophthalmoscopy exam ination  (including cup- disc ratio)
Subjects will be: 
•Instructed to continue to self- administer th eir masked medication at home between
20:00 - 22:00 hours (8 PM and 10 PM, beginning with the evening dose on that day)
•Instructed to return to the office with their study medication on Month 6 (Day 180 )
•A new packer containing 3 kits will be dispensed to the subject, along with storage
instructions
7.1.15 Visit 7 .0 (Month 6 [Day 180], for IOP and safety measurement s at 08:00 
hours ) 
Subjects will return to the Investigator’s office with their study medication.  The subject will 
be questioned about any missed doses and any changes in their health or concomitant medication use.  
Subjects will be examined and each examination will include: 
•Heart rate and blood pressure
•Urine Pregnancy Test (female subjects of childbearing potential; as applicable)
•
Blood samples wi ll be taken for clinical chemistry and hematology (see Appendix 1). 
Note t
hat these samples may b e taken at an y time of  the day
•Symptomat
ology: Individuals will be asked “How are you feeling?”
•Recording of any AEs
PG324 Ophthalmic Solution  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
Confidential  Page 73 of 123 •Comfort Test: Individuals will be asked “Did you experience any discomfort when
placing the drops in your eyes?”
•Best corrected visual acuity
•A non- dilated eye examination will be performed, including pupil size, IOP and
biomicroscopy
oIOP must be measured within 30 minutes of the nominal time (ie, 07:30 to
08:30 hours)
•Pachymetry at the study visit or within one week of the study visit
•Visual fields (Note: may be assessed up to one week prior to this visit, or later in the
morning or afternoon of this series of Day 180 visits so long as it occurs after IOP
measurement at that visit). See  Appendix 2 for further details when dilation is
required due to subject small pupils
•Collect study medication from the subject.
After randomization, any new or worsening of symptoms beyond those collected at baseline are to be entered as adverse events.  
Subjects are allowed to leave the Investigator’s office on the day of this study visit between assessments, and eat and drink without restrictions.  However, individuals are not to consume alcohol or engage in strenuous exercise. 
7.1.16 Visit 7.1 (Month 6 [Day 180], for IOP and safety measurements at 10:00 
hours)  
Subjects will be examined and each examination will include: 
•Symptomatology: Individuals will be asked “How are you feeling?”
•A non- dilated eye examination will be performed, including IOP and  biomicroscopy
oIOP must be measured within 30 minutes of the nominal time (ie, 09:30 to10:30 hours)
Subjects are allowed to leave the Investigator’s office on the day of t his study visit between 
assessments, and eat and drink without restrictions.  However, individuals are not to consume alcohol or engage in strenuous exercise. 
7.1.17 Visit 7.2 (Month 6 [Day 180}, for IOP and safety measur ements at 16:00 
hours)  
Subjects will be ex amined and each examination will include: 
PG324 Ophthalmic Solution  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
Confidential  Page 74 of 123 •Symptomatology: Individuals will be asked “How are you feeling?”
•A non- dilated eye examination will be performed, including IOP and  biomicroscopy
oIOP must be measured within 30 minutes of the nominal time (ie, 15:30 to
16:30 hours)
•A dilated ophthalmoscopy examination (including cup- disc ratio)
Subjects will be: 
•Instructed to continue to self- administer their masked medication at home between
20:00 - 22:00 hours (8 PM and 10 PM, beginning with the evening dose on that day)
•Instructed to return to the office with their study medication on Month 9 (Day 270)
•A new packer containing 3 kits will be dispensed to the subject, along with storage
instructions
7.1.18 Visit 8 .0 (Month 9 [Day 270], for IOP and safety measurements at 08:00 
hours)  
Subjects will return to the Investigator’s office with their study medication.  The subject will 
be questioned about any missed doses and any changes in their health or concomitant medication use.  
Subjects will be examined and each examination will include: 
•Heart rate and blood pressure
•Urine Pregnancy Test (female subjects of childbearing potential; as applicable)
•Symptomatology: Individuals will be asked “How are you feeling?”
•Recording of any AEs
•Comfort Test: Individuals will be asked “Did you experience any discomfort when
placing the drops in your eyes?”
•Best corrected visual acuity
•A non-dilated eye examination will be performed, including IOP and biomicroscopy
oIOP must be measured within 30 minutes of the nominal time (ie, 07:30 to
08:30 hours)
•Collect study medication from the subject.
PG324 Ophthalmic Solution   
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 75 of 123  
   
 After randomization, any new or worsening of symptoms beyond those collected at baseline 
are to be entered as adverse events.  
Subjects are allowed to leave the Investigator’s office on the day of t his study visit between 
assessments, and eat and drink without restrictions.  However, individuals are not to consume alcohol or engage in strenuous exercise. 
7.1.19 Visit 8.1 (Month 9 [Day 270], for IOP and safety measurements at 10:00 
hours)  
Subjects will be ex amined and each examination will include: 
• Symptomatology: Individuals will be asked “How are you feeling?” 
• IOP measurement  
o IOP must be measured within 30 minutes of the nominal time (ie, 09:30 to 10:30 hours) 
Subjects are allowed to leave the Investigator’ s office on the day of this study visit between 
assessments, and eat and drink without restrictions.  However, individuals are not to consume alcohol or engage in strenuous exercise. 
7.1.20 Visit 8.2 (Month 9 [Day 270], for IOP and safety measurements at 16:00 
hours) 
• Symptomatology: Individuals will be asked “How are you feeling?” 
• IOP measurement  
o IOP must be measured within 30 minutes of the nominal time (ie, 15:30 to 16:30 hours) 
Subjects will be: 
• Instructed to continue to self- administer their masked medication at home between 
20:00 - 22:00 hours (8 PM and 10 PM, beginning with the evening dose on that day)   
• Instructed to return to the office with their study medication on Month12 (Day 365)   
• A new packer containing 3 kits will be dispensed to the subject, along with storage 
instructions 
PG324 Ophthalmic Solution  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
Confidential  Page 76 of 123 7.1.21 Visit 9 .0 (Month 12 [Day 365], for IOP and safety measurement s at 08:00 
hours)  
Subjects will return to the Investigator’s office with their study medication.  The subject will 
be questioned about any missed doses and any changes in their health or concomitant medication use.  
Subjects will be examined and each examination will include: 
•Heart rate and blood pressure
•Urine Pregnancy Test (female subjects of childbearing potential; as applicable)
•
Blood samples will be taken for clinical chemistry and hematology ( see Appendix 1). 
Note t
hat these samples may b e taken at an y time of  the day
•Symptomat
ology: Individuals will be asked "How are you feeling?"
•Recording of any AEs
•Comfort Test: Individuals will be a sked "Did you experience any discomfort when
placing the drops in your eyes?"
•Best corrected visual acuity
•A non-dilated eye examination will be performed, including pupil size, IOP and
biomicroscopy
oIOP must be measured within 30 minutes of the nominal time (ie, 07:30 to
08:30 hours)
•Visual fields (Note: may be assessed up to one week prior to this visit, or later in the
morning or afternoon of this series of Day 365 visits so long as it occurs after IOP
measurement at that visit). See  Appendix 2 for further details when dilation is
required due to subject small pupils
•Collect study medication from the subject.
After randomization, any new or worsening of symptoms beyond those collected at baseline are to be entered as adverse events. 
Subjects are allowed to leave the Investigator's office on the day of this study visit between 
assessments, and eat and drink without restrictions.  However, individuals are not to consume alcohol or engage in strenuous exercise. 
PG324 Ophthalmic Solution  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
Confidential  Page 80 of 123 •H02:  The difference between study eyes treated with PG324  Ophthalmic Solution  and
study eyes treated with AR -13324 Ophthalmic Solution, 0.02%
(PG324 − AR -13324), in mean IOP at  the following time points: 08:00, 10:00, and
16:00 hours at the Week 2, Week 6, and Month 3 Visits, is ≥ 0 mmHg for at least one
time point over all visits.
•H12:  The difference between study eyes treated with PG324  Ophthalmic Solution  and
study eyes treated with AR -13324 Ophthalmic Solution, 0.02%
(PG324 − AR -13324), in mean IOP at  the following time points: 08:00, 10:00, and
16:00 hours at the Week 2, Week 6, and Month 3 Visits, is < 0 mmHg for all timepoints over all visits.
The study will be considered a success if both H
01 and H 02 are rejected.  
9.2 Sample Size Considerations 
Efficacy: 
One-hundred ninety six (196) subjects per arm completing 3 months of treatment yields at 
least 90% power to conclude statistical superiority of PG324 to latanoprost and >99% power to conclude statistical superiority of PG324 to AR-13324 at all nine time points assuming a two-sided alpha = 0.05, a true mean difference of 1. 5 mmHg (to latanoprost) and 2.0 mmHg 
(to AR -13324), a common standard deviation of 3.5 mmHg at each time point, and 
independence among time points.  Power increases as the correlation among time points increases.  Therefore, 196 subjects per arm yield at least 90% power to conclude superiority 
to both controls over all nine time points.   
9.3 Analysis Populations  
Randomized Population: The randomized population will include all subjects who were 
randomized to treatment.  Baseline variables and demographic characteristics will be 
summarized for this population. 
Intent- to-Treat Popula tion (ITT):  The ITT population will include all randomized subjects 
who have received at least one dose of study medication.  This population will be the primary population for efficacy analyses and will be used to summarize all efficacy variables and will  
summarize subjects as randomized. 
Per-protocol population (PP): The PP population is a subset of the ITT population, which 
will include those subjects (and their visits) who do not have major protocol violations likely to seriously affect the primary outcome of the study as judged by a masked evaluation prior to the unmasking of the study treatment.  This population will be the secondary population for efficacy analyses and will be used to summarize a subset of efficacy variables.  If the PP 
and ITT popula tions are exactly the same, then additional efficacy analyses on the PP 
population will not be performed.  The PP population will summarize subjects as treated. 
PG324 Ophthalmic Solution  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
Confidential  Page 81 of 123 Safety Population: The safety population will include all randomized subjects who have 
received  at least one dose of study medication.  This population will be used to summarize 
safety variables and will summarize subjects as treated.   
9.4 Statistical Methods to be Employed 
9.4.1 General Considerations 
All continuous study assessments will be summarized by treatment and time point 
(as applicable) using descriptive statistics (n, mean, median, standard deviation, minimum, 
and maximum).  All categorical study assessments will be summarized by treatment and time point (as applicable) using frequency counts and percentages.   
Hypothesis testing, unless otherwise indicated, will be performed at a 2 -sided 
0.05 significance level.  When applicable, two -sided 95% confidence intervals will be 
reported.  All p- values will be displayed to four decimal places, with p -values less than 
0.0001 presented as '<0.0001' and p-values greater than 0.9999 presented as ‘>0.9999’.  Differences between PG324 and each  comparator (latanoprost and AR-13324) will be 
calculated as PG324 – comparator.   
All study data will be listed by trea tment, subject and time point (as applicable).  
For diurnally- adjusted IOP, baseline will refer to the  time -relevant measure at Visit  3.0 
through 3.2 ( eg, IOP at 08:00 hours at Visit 3.0 will be the baseline for 08:00 hours at 
Visit 4.0, Visit 5.0, and Visit 6.0; IOP at 10:00 hours at Visit 3.1 will be the baseline for 
10:00 hours at Visit 4.1, Visit 5.1, and Visit 6.1; etc.).  For all other variables, baseline is 
defined as the last measurement prior to the first dose of study medication.  
The unit of ana lysis for efficacy will be the study eye.  For a subject who qualifies, the study 
eye will be the eye with the higher IOP  at 08:00 hours on Visit 3.  If both eyes have the same 
IOP at 08:00 hours on Visit 3, then the right eye will be the study eye. Data collected during the observation extension visits may be summarized separately from 
the data collected during the main portion of the study. Statistical methods will be more fully described in separate document(s) (ie, the Statistical 
Analysis Plan).   
9.4.2 Interim Analyses 
When all subject s have completed three months of treatment, the Sponsor will unmask the 
study to analyze the 3 month efficacy and safety data.  This is the time for primary efficacy  
analysis of the study.  Efforts will be made to keep the Inve stigators , site staff, and subjects 
masked as to individual subject  assignments , as the subject s continue to be evaluated for 
safety for the following 9 months. The Sponsor will conduct an additional data base lock and 
unmask the study when all subject s have complete d the ir 12 month visit. This is the time for 
primary analysis of the 12 month safety data. Interim analyses will be conducted so as to 
PG324 Ophthalmic Solution  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
Confidential  Page 83 of 123 •Percentages of subjects achieving pre- specified mean, mean change, and percent
mean change diurnal IOP levels
Other secondary efficacy analyses will be conducted as  described in the study Statistical 
Analysis Plan.  Note that each subject will have one eye designated as the study eye.  
Only  the study eyes will be evaluated for the primary efficacy measure or for selected 
secondary efficacy measures; however, both eyes will be treated.   Qualifying fellow eyes 
will be evaluated separately for the primary analysis of the primary efficacy measure.    
The primary analysis of the primary outcome will employ a linear model with mean IOP at 
the given visit (Week 2, Week 6, and Month 3) and time point (08:00, 10:00, and 16:00 hours ) as the response, baseline IOP as a covariate, and treatment as a main effect 
factor, using the intent to treat population with multiple imputation techniques (eg, Monte Carlo Markov Chain) used to impute missing data.  Each time point within each 
visit will be modeled separately.  The least squares mean differences (test – control) between 
PG324 Ophthalmic Solution and each of Latanoprost Ophthalmic Solution, 0. 005% and 
AR-13324 Ophthalmic Solution, 0.02% will be presented as well as 2-sided p-values and 
95% confidence intervals. For a given comparator (latanoprost and AR-13324), if the p- value 
is P < 0.05 and the point estimate < 0 for all time points at the We ek 2, Week 6, and Month 3 
Visits , then the corresponding null hypothesis will be rejected in favor of the alternative 
hypothesis and PG324 will be considered to be superior to the comparator.  Results will be presented in both tabular and graphical form. 
Analyses will be performed primarily on the ITT population using multiple imputation 
techniques to impute missing data and secondarily using: observed data only, last observation carried forward (LOCF) where LOCF will be performed using time- relevant measures; and 
baseline observation carried forward (BOCF) using time- relevant measures to determine the 
robustness of results.  Additionally, the above analyses will be repeated on the PP population to determine robustness of results.  Additional imputation techniques may be designated in the formal statistical analysis plan.   Sam ple SAS code to demonstrate the methodology that 
will be used for data imputation can be found in Appendix 7.  
Secondary analyses of the primary endpoint will be  completed using individual two- sample 
t-tests and 95% t-distribution confidence intervals for each comparison (PG324 vs latanoprost and AR-13324) at each time point (08:00, 10:00, and 16:00 at the Week 2, Week  6, and Month 3 Visits) using the ITT population. Similar analyses will be completed 
on the secondary endpoints: mean IOP measure at each time point and visit and mean diurnal IOP and change from baseline diurnal IOP measures.  M odels adjusting for baseline will only 
be performed on the mean IOP respo nse variable as inference is identical between this 
response and the change from baseline IOP response variable in such a model.  
Additionally, for the mean  IOP values at each time point, mixed model repeated measures 
will be run with baseline as the covari ate; treatment, visit, time point, treatment by visit, 
treatment by time point, visit by time point, and treatment by visit by time point as the fixed effect factors; and subject as the random effect, repeated measure.  An unstructured covariance structure will be used to model the within subject, between visit and time point 
PG324 Ophthalmic Solution  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
Confidential  Page 86 of 123 presented separately for ocular and non -ocular AEs.  These summaries will also be presented 
for relation to Investigational Product and by severity.  Fisher’s exact test will be used to test 
the difference in proportions of subjects with each AE between treatment groups (SOC  and PT).   
9.5 Procedure for Accounting for Missing, U nused, or Spurious Data   
Analyses will be performed primarily  on observed data only (without imputation) and 
secondarily using: last observation carried forward (LOCF) where LOCF will be performed using time -relevant measures (ie, from the same time point of the most recent visit with a 
non-missing value); BOCF using time -relevant measures; and using multiple imputation 
methods to determine the robustness of results.  Any missing, unused, or spurious data will be noted in the final statistical report.  
9.6 Procedure for Reporting Deviations from the S tatistical Plan   
Any deviations from the statistical plan will be described and a justification given in the final 
statistical report.  
9.7 Data L istings    
Data listings will be prepared for all data on the database.  
10.ADMINISTRATIVE CONSIDERATIONS
10.1 GCP compliance  
The proposed study is subject  to all applicable governmental rules and regulations 
concerning the conduct of clinical trials on human subject s.  This includes, but is not 
necessarily limited to :  
•Approval of properly constituted Institutional Review Boards
•
Helsinki Declaration (S ee Appendix 6)
•U.S. FDA L
aw
•ICH GCP guidelines
•Obtaining prospective informed consent
•Monitoring of the conduct of the study
•Completeness of the Case Report Forms by the Sponsor or its designee(s)
•Appropriate record retentio n by the Investigator.
Protocol change or amendment procedures, applicable IRB requirements , 
Investigator/Sponsor obligations, and  study monitoring procedures  are detailed  in 
Section  10.2 through Section  10.8 of this protocol.  
PG324 Ophthalmic Solution  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
Confidential  Page 89 of 123 agencies) may be granted direct access to the study subject ’s original medical and study 
records for verification of the data or clinical study procedures. Access to this information 
will be permitted to representatives of the aforementioned organizations to the extent permitted by law.  
A report of this study’s results may be published or sent to the appropriate health authorities in any country in which the study drug may ultimately be marketed, but subject  identities will 
not be disclosed in these documents. 
10.8 Study Monito ring 
Clinical research associates hired or contracted by the Sponsor will be responsible for  
monitoring the study sites and study activities.  They will contact and visit the Investigator  
regularly.  The actual frequency of monitoring visits depends on subject  enrollment and on 
study site performance.  Among others, the following items will be reviewed: 
•Study progress
•Compliance with the protocol
•Completion of CRFs
•Dispensing, storage, and accountability of IP, including intentional or inadvertent
unmasking of IP
•Source data verification
•AE and SAE reporting
•Essential documents contained within the regulatory binder
For source data verification (ie, comparison of CRF entries with subject  records), data will be 
100% source verified and will include as a minimum :  
•Subject  identification
•Informed consent (procedure, signature, and date)
•Selection criteria
•Primary efficacy and safety parameters (ie, AEs)
Member(s) of the Sponsor or their designee will meet with the Investigator prior to the 
initiation of the study in order to assess the adequacy of the Investigator's subject  population, 
facilities, and equipment, and to familiarize the Investigator with the protocol.  
PG324 Ophthalmic Solution  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
Confidential  Page 90 of 123 A member of the Sponsor or their designee in the role of Study Monitor will subsequently 
meet with the Investigator after several of the subject s have initiated the study in order to 
ensure that the subjects are being properly selected, that adequate supplies for the study have 
been provided and that the assignment of medication is properly recorded. In addition, the 
Study Monitor will verify that the Investigator follows the approved protocol and all approved amendments, if any, by reviewing the Investigator’s regulatory documents, source documents, Informed Consent Forms, and Case Report Forms of st udy subject s. 
The Study Monitor will meet with the Investigator when all subjects have completed the 
Final Visit of the study, in order to collect the Case Report Forms, unused study medications, and unused supplies and materials. 
Interim monitoring visits  and telephone consultations will be done by the Study Monitor as 
necessary, to ensure the proper progression and documentation of the study. 
10.9 Case Report Forms and Study Records  
The initial point of entry of study data should be the subject  source documentation.  The 
location and nature of the source documentation for all data collected in the study will be 
identified in the study files at the investigator’s site.  In cases where no source documents will be used (ie, data will be recorded directly onto the case report form (CRF) without first being recorded on another document, such as a flowsheet, laboratory report, or other typical form of data reporting for later transcription to the CRF), the original data will be included in the CRF.   
Source document information should be legible. Recorded data should only be corrected by drawing a single line through the incorrect entry and writing the revision next to the corrected data. The person who has made the correction should place his or her initials as well as  the date of the correction next to the correction. Data may not be obliterated by 
erasure, redaction, or with correction fluid. 
Study data will be transcribed and recorded via an electronic data capture (EDC) system as 
electronic CRFs (eCRFs). Security an d authorization procedures consistent with the EDC 
system must be used. At each subject visit, the appropriate eCRFs must be completed.  
Whenever an eCRF is used, be sure to provide all information requested including subject  
identification number and initials, name or number of I nvestigator, date(s), etc.  
All applicable questions should be answered and all data requested should be provided.  
Those areas that require a response but are not filled in correctly are considered incomplete 
or erroneous entries, and will have to be corrected.   
Each authorized study staff member will receive a unique access account in order to use the EDC system. Access accounts will not be shared among study staff. Authorized users will make entries and/or changes to eCRF s via a secure internet access. Each completed set of  
eCRFs will be reviewed by the Investigator who will then electronically sign and date the  
eCRF confirming that data for the subjects are complete and accurate.  
PG324 Ophthalmic Solution  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
Confidential  Page 91 of 123 The study records must include a copy of each Investigator's CV and medical license,  
completed, FDA Form 1572 or statement of Investigator, each eCRF, subject charts/source 
documents, Investigator’s Brochure, protocol, protocol amendments, correspondence with the Sponsor and the IRB/IEC, IP storage, receipts, returns and dispensing records, Delegation of Responsibilities Log, site training records, records of site monitoring, any unmasking 
documentation, AE and SAE reporting, IRB/IEC approvals, advertisements, written information provided to subject s, and subject  completed ICFs. If the Investigator  moves, 
withdraws from an investigation, or retires, the responsibility for maintaining the records may be transferred to another person ( eg, Sponsor, other Investigator) who will  accept the 
responsibility. Notic e of this transfer, including written acceptance, must be made to and 
agreed upon by the Sponsor. 
10.10 Protocol Deviations 
A protocol deviation occurs when there is non- adherence to study procedures or schedules 
which does not involve inclusion/exclusion criteria or the primary efficacy endpoint and 
which does not place the subject  at any added risk or affect the data quality or study outcome. 
Examples of deviations include common out of window visits or timed procedures, a missed procedure, etc. Sites will reco rd protocol deviations in the study records. To the extent 
possible, sites will make their best efforts to quickly remedy deviations.  
The site will contact the Sponsor for clarification of inclusion/exclusion criteria as needed prior to enrollment of a study subject . The Sponsor will document clarification requests and 
responses. If a potential subject  does not meet all inclusion and exclusion criteria during 
screening, that subject may not be enrolled in the study. 
The site will notify the Sponsor or their representative and IRB/IEC within 10 days of becoming aware of any significant protocol deviation. Typically, significant protocol deviation include significant deviations from the inclusion and exclusion criteria that may impact interpretation or the qua lity of efficacy information or the safety of a subject , 
concomitant medication restrictions, or any other protocol requirement that results in a significant added risk to the subject  or has an impact on the quality of the data collected or 
the outcome of the study. 
The Sponsor will review, designate, and/or approve all protocol deviations prior to database 
lock. 
10.11 Access to Source Documentation  
Monitors, auditors, and other authorized representatives of the Sponsor, the governing 
IRB(s)/IEC(s), the FDA, the DHHS, other domestic government agencies, and other foreign 
regulatory agencies will be granted direct access to the study subject ’s original medical and 
study records for verification of the data and/or clinical study procedures. Access to this informatio n will be permitted to representatives of the aforementioned organizations to the 
extent permitted by law.  
PG324 Ophthalmic Solution  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
Confidential  Page 92 of 123 10.12 Data Generation and Analysis 
After data have been entered into the study EDC system database, a system of computerized 
data validation checks will be implemented and applied to the database.  Query reports 
pertaining to data omissions and discrepancies will be forwarded to the clinical Investigator and the Sponsor for resolution.  Where required, the Investigator will be asked for supplementary information through a query.  The study EDC system database will be 
updated by the clinical investigator or their staff, in accordance with the resolved query reports.  All changes to the study database will be documented.   
Once the eCRFs are monitored in the ED C system, the data management CRO and the 
Sponsor will further check the eCRFs for completeness and plausibility of the data. The data 
management CRO will use quality systems in order to verify accurate and complete  data 
entry, including additional checks of the data once entered in a database (eg, range checks,  cross checks and other edit checks).  
All procedures for the handling and analysis of data will be conducted using good computing practices meeting ICH and US Food and Drug Administration (FDA) guidelines for the handling and analysis of data for clinical trials.  Data will be checked per the data management CRO ’s SOPs. The database then will be locked and a biostatistician will 
complete the analyses of the data in accordance with the Statistical Analysis Plan.  
10.13 Retention of Data  
Archived versions of the EDC system database will be saved by the Sponsor consistent with ICH Good Clinical Practices Guidelines.  The Sponsor will notify the investigator when documents should be returned.   
The Investigator’ s site and the study clinical laboratory will retain all records related to the 
study in compliance with ICH Good Clinical Practices Guidelines and 21 CFR 312.57(c)  
(see Appendix 5 for additional investigator obligations ).  
10.14 Finan cial Disclosure  
The Principal Investigator and Sub-investigators (as listed on Form FDA 1572) will provide financial disclosure information prior to participation in the study. The Principal Investigator and any Sub-investigators will notify the Sponsor promptly of any required revision to their financial disclosure status during the term of this study, annually, or at the end of the study (if applicable). The Principal Investigator and Sub-investigators will provide updated financial disclosure information  upon the Sponsor’s written request following completion of 
the study. 
10.15 Publication and Disclosure Policy  
Aerie Pharmaceuticals , as the Sponsor, has proprietary interest in the study. Authorship and 
manuscript composition will reflect joint cooperation between multiple investigators and 
sites and Aerie Pharmaceuticals personnel.  As this study involves multiple centers, no 
PG324 Ophthalmic Solution  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
Confidential  Page 93 of 123 individual publications will be allowed prior to completion of the final report of the 
multicenter study except as agreed with Aerie Phar maceuticals.  
PG324 Ophthalmic Solution  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
Confidential  Page 94 of 123 11.REFERENCES
11.1 Published References  
1. Chen J, Runyan SA, Robinson MR.  Novel ocular antihypertensive compounds in
clinical trials. Clin Ophthalmol 2011; 5:667 -77.
2. Collaborative Normal-Tension Glaucoma Study Group.  The effectiveness of
intraocular pressure reduction in the treatment of normal-tension glaucoma.  Am J
Ophthalmol 1998; 126:498-505.
3. Ferris FL and Bailey I.  Standardizing the measurement of visual acuity for clinical
research studies.  Ophthalmol 1996; 103:181-82.
4. Ferris FL, Kassoff, A, Bresnick GH, et al.  New visual acuity charts for clinical
research.  Am J Ophthalmol 1982; 94:91-6.
5. Heijl A, Leske MC, Bengtsson B, et al.  Reduction of intraocular pressure and
glaucoma progression: results from the Early Manifest Glaucoma Trial.  ArchOphthalmol 2002; 120: 1268-79.
6. Hughes BA, Bacharach J, Craven ER, et al. A three-month, multicenter, double-
masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5%ophthalmic solution compared to travoprost 0.004% ophthalmic solution and t imolol
0.5% dosed concomitantly in subjects with open angle glaucoma or ocularhypertension. J Glaucoma 2005;14:392-9.
7. Jabs DA, Nussenblatt RB, Rosenbaum JT.  Standardization of uveitis nomenclature
for reporting clinical data. Results of the First Interna tional Workshop.  Am J
Ophthalmol 2005; 140:509-16.
8. Kass MA, Gordon MO, Gao F, et al. Delaying Treatment of Ocular Hypertension:
The Ocular Hypertension Treatment Study. Arch Ophthalmol 2010;128:276-87.
9. Kiel JW, Kopczynski C. Effect of AR-13324 on episcleral venous pressure in Dutch
Belted rabbits. J Ocul Pharmacol Ther  2015; 31(3):146-51.
10. Kolker AE, Hetherington J Jr, eds.  Becker and Shaffer’s diagnosis and therapy of the
glaucomas, 5th ed.  St Louis: CV Mosby, 1976.
11. Kopczynski CC and Epstein DL.  Emerging Trabecular Outflow Drugs. J Ocul
Pharmacol Ther 2014; 30:85-7.
12. Sherwood MB, Craven ER, Chou C, et al. Twice-daily 0.2% brimonidine-0.5%
timolol fixed -combination therapy vs. monotherapy with timolol or brimonidine in
patients with glaucoma or ocular hypertension: a 12-month randomized trial. ArchOphthalmol 2006;124:1230-8.
13. Stone JL, Robin AL, Novack GD, et al. An objective evaluation of eye-drop
instillation in glaucoma patients. Arch Ophthalmol 2009;127:732-6.
PG324 Ophthalmic Solution  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
Confidential  Page 95 of 123 14. The AGIS Investigators. The Advanced Glauco ma Intervention Study (AGIS): 7. The
relationship between control of intraocular pressure and visual field deterioration. Am
J Ophthalmol 2000;130:429-40.
15. Wang  R-F, Williamson  JE, Kopczynski C,  et al. Effect  of 0.04% AR -13324, a ROCK
and Norepinephrine Tra nsporter Inhibitor, on Aqueous Humor Dynamics  in
Normotensive Monkey Eyes.  J Glaucoma, 2015; 24:51-4.
16. Wang  SK and Chang  RT.  An emerging  treatment  option for glaucoma:  Rho kinase
inhibitors.  Clin  Ophthalmol 2014; 8:883-90.
17. Williams  RD, Novack  GD,  Van  Haarlem  T, et al.  Ocular  hypotensive effect  of the
rho kinase inhibitor AR -12286 in  patients  with  glaucoma and  ocular  hypertension.
Am J Ophthalmol 2011; 152:834-41.
11.2 Internal References  
1. Aerie Pharmaceuticals,  Inc., AR-13324 Investigator’s Brochure, 201 7.
2. AR-13324-CS101 Cli
nical Study Report: An Open -Label Study Assessing the Ocular
and Systemic Safety and Systemic Absorption of AR-13324 Ophthalmic Solution,0.02% in Healthy Volunteers (2014).
3. AR-13324-CS201 Clinical Study Report: A Phase 2, double- masked, ran domized,
placebo -controlled, dose- response study assessing the safety and ocular hypotensive
efficacy of three doses of AR -13324 Ophthalmic Solution in patients with elevated
intraocular pressure (2012).
4. AR-13324-CS202 Clinical Study Report: A phase 2, double-masked, randomized,
multi- center, active -controlled, dose- response parallel -group study comparing the
safety and ocular hypotensive efficacy of AR -13324 to latanoprost in patients with
elevated intraocular pressure (2013).
5. PG324-CS201 Clinical Study Report: A double-masked, randomized, controlled
study assessing the safety and ocular hypotensive efficacy of PG324 OphthalmicSolution, 0.01% and PG324 Ophthalmic Solution, 0.02%, compared to AR-13324Ophthalmic Solution, 0.02% and Latanoprost Ophthalmic Solution, 0.005% inpatients with elevated intraocular pressure (2014).
6. AR-13324-CS301 Clinical Study Report: A double-masked, randomized, multi-
center, active-controlled, parallel, 3-month study assessing the safety and ocularhypotensive efficacy of AR -13324 Ophthalmic Solution, 0.02% compared to timolol
maleate ophthalmic solution, 0.5% in patients with elevated intraocular pressure(2016)
PG324 Ophthalmic Solution   
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 96 of 123  
   
 Appendix  1 Schedule of Visits and Examinations 
Day/Week/Month  Scree
n Qual  
#1 Qual. #2  
D1 Post D1 Treatment Period Assessments  Observational 
Period  
W2 
(Day  15±3)  W6 
(Day  43±3)  M3, M6  
(Day  90±3 , Day 
180±7) M9 
(Day  270±7)  M12 
(Day  365±7)  M13 
(D395±
7) M14 
(D425±
7) 
Visit  1 2 3.0 3.1 3.2 4.0 4.1 4.2 5.0 5.
1 5.2 6.0, 
7.0 6.1, 
7.1 6.2, 
7.2 8.0 8.1 8.2 9.0 9.1 9.2 10 11 
Hour  (XY = XY:00)   08 08 10 16 08 10 16 08 10 16 08 10 16 08 10 16 08 10 16 08 08 
Informed Consent  X                   X12   
Inclusion/Exclusion  X X X X X                  
Washout1 X                      
Demography  X                      
Medical/Ophthalmic Hist . X X X                    
Concomitant Medications  X X X   X   X   X   X   X   X X 
HR/BP  X X X   X   X   X   X   X     
 Urine P regnancy Tes t2 X           X   X   X     
Clinical  Labs (Chem/Hem)   X3           X       X     
Symptoms/AE s4 X X X X X X X X X X X X X X X X X X X X X X 
 Comfort Tes t5      X   X   X   X   X     
Visual Acuity (ETDRS)  X X X   X   X   X   X   X   X X 
Pupil size    X         X      X     
IOP X X6 X6 X6 X6 X X X X X X X X X X X X X X X X X 
Biomicroscopy  X X X X X X X X X X X X X X X   X   X X 
Gonioscopy7/ Pachymetry8 G/P           P           
Visual Field9 X           X      X    X 
Ophthalmoscopy (dilated)  X             X    X11  X  X 
Eye-Drop Instillation Eval . X                      
Study Meds Dispensed      X   X   X   X   X      
Collect Study Meds       X10   X10   X10   X10   X10     
Study Completed                   X13    X13 
Abbreviations:  D, day; W, week; M, month; Med/Ophthalmic Hist, Medical/Ophthalmic History; HR/BP, heart rate/blood pressure; Clin Labs,  
Clinical Labs (Chemistry/Hematology); G, gonioscopy; P, pachymetry; AE, adverse event; ETDRS, early treatment diabetic retino pathy study; IOP, intraocular pressure 
 
PG324 Ophthalmic Solution   
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 97 of 123  
   
 Appendix 1  Schedule of Visits and Examinations (cont’d)  
1 Subjects currently using ocular hypotensive medications must under go a minimum washout period (Table  1 for de tails).  
2 Urine pregnancy test for wom en of childbearing potential is required.  
3 For subjects who are unable or unwilling to have blood drawn for clinical labs at Visit 1 (screening), the blood sample may be drawn at Visit 2 (Qualification  Visit #1) 
so long as the results of the clinical labs are available for that subject prior to Visit 3 (Qualification Visit #2).  
4 Ocular symptoms: Subjects will be queried at each visit “How are you feeling?” and treatment emergent AEs beginning at Visit 3 (Qualification Visit #2) will be 
documented on the AE form. Additional symptoms reported after screening and before randomization will be documente d on the medical history form.  
5 Comfort test: At 08:00 hour for study drug visits, subjects will be queried “Did you experience any discomfort when placing the drops  in your eyes?”  
6 Individuals returning at an unscheduled visit within 1 week are required to only remeasure IOP in both eyes ( Section  7.1.2  to Section  7.1.5 ). 
7 Gonioscopy evaluation up to 3 months prior to randomization is acceptable.  
8 Pachymetry within one week of study visit  is acceptable. 
9 Entry visual field evaluation up to 3 months prior to randomization is acceptable.  Visual field collection must meet the req uiremen t for automated threshold visual 
field assessment (eg, 30 -2 or 24- 2 Humphrey) and reliability.  
10 Collect used kit(s) dispensed during the previous visit.  
11 Ophthalmoscopy (dilated) at Visit 9.0 at 08:00: this assessment should be performed for all non- completi ng subjects during the exit visit.  
12 Informed consent must be completed by the subjects before entering the extension visits.  
13 Month 12 visit completed for the treatment period. Month 14 visit completed for the subjects entering the extension visits of  the st udy.  
 
PG324 Ophthalmic Soluti on  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 105 of 123  
   
 Appendix  3 Marketed Product Information: Latanoprost Ophthalmic Solution, 
0.005% 
The following is taken from the most recent package insert as of the date of this protocol for 
latanoprost ophthalmic solution 0.005% as marketed by Bausch & Lomb. 
 
HIGHLIGHTS OF PRESCRIBING INFORMATION  
These highlights do not include all the information needed to use LATANOPROST safely and effectively. See full prescribing information for LATANOPROST. LATANOPROST (latanoprost ophthalmic solution) 0.005% Initial U.S. Approval: 1996 
------------------INDICATIONS AND USAGE -------------------  
Latanoprost is a prostaglandin F2α analogue indicated for the reduction of elevated 
intraocular pressure in patients with open- angle glaucoma or ocular hypertension. (1) 
 --------------DOSAGE AND ADMINISTRATION----------------  
One drop in the affected eye(s) once daily in the evening. ( 2) 
 ------------ DOSAGE FORMS AND STRENGTHS --------------  
Ophthalmic solution containing 50 mcg/mL latanoprost (0.005%). (3 ) 
 --------------------CONTRAINDICATIONS ----------------------  
Known hypersensitivity to latanoprost, benzalkonium chloride, or any other ingredients in 
this product. (4 ) 
-------------WARNINGS AND PRECAUTIONS ----------------  
• Pigmentation: pigmentation of the iris, periorbital tissue (eyelid) and eyelashes can occur. 
Iris pigmentation likely to be permanent. ( 5.1) 
• Eyelash Changes: gradual change to eyelashes including increased length, thickness and 
number of lashes. Usually reversible. (5.2) 
 --------------------ADVERSE REACTIONS ----------------------  
Most common adve rse reactions ( ≥4%) from clinical trials are blurred vision, burning and 
stinging, conjunctival hyperemia, foreign body sensation, itching, increased pigmentation of the iris, punctate epithelial keratopathy, and upper respiratory tract infection/cold/flu. (6 ). 
To report  SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb at 1 -800-
323-0000 or FDA at 1-800- FDA-1088 or www.fda.gov/medwatch . 
 --------------------DRUG INTERACTIONS ----------------------  
In vitro studies have shown that precipitation occurs when eye drops contai ning thimerosal 
are mixed with Latanoprost.  If such drugs are used, they should be administered at least 5 minutes apart. (7 ) 
See 17 for PATIENT COUNSELING INFORMATION 
Revised: 02/2015 
PG324 Ophthalmic Soluti on  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 106 of 123  
   
  
FULL PRESCRIBING INFORMATION: CONTENTS*  
1          INDICATIONS AND US AGE  
2          DOSAGE AND ADMINISTRATION 
3          DOSAGE FORMS AND STRENGTHS  
4          CONTRAINDICATIONS  
5          WARNINGS AND PRECAUTIONS  
5.1        Pigmentation 5.2       Eyelash Changes 5.3        Intraocular Inflammation 5.4        Macular Edema  
5.5        Herpetic Keratitis  
5.6        Bacterial Keratitis  
5.7        Use with Contact Lenses 
6          ADVERSE REACTIONS  
6.1       Clinical Trials Experience 6.2        Postmarketing Experience 
7          DRUG INTERACTIONS  
8          USE IN SPECIFIC POPULATIONS  
8.1        Pregnancy 8.3        Nursing Mother s 
8.4        Pediatric Use 8.5        Geriatric Use  
10        OVERDOSAGE  
11        DESCRIPTION  
12        CLINICAL PHARMACOLOGY  
12.1      Mechanism of Action 12.2      Pharmacodynamics 12.3      Pharmacokinetics 
13        NONCLINICAL TOXICOLOGY 
13.1      Carcinogenesis, Mutagenesis, Impairment of Fertility 
14        CLINICAL STUDIES  
14.1     Elevated Baseline IOP 14.2      Progression of Increased Iris Pigmentation 
16        HOW SUPPLIED/STORAGE AND HANDLING  
17        PATIENT COUNSELING INFORMATION 
17.1      Potential for Pigmentation  
17.2      Potential for Eyelash Changes 17.3      Handling the Container 17.4      When to Seek Physician Advice 17.5      Use with Contact Lenses 17.6      Use with Other O phthalmic Drugs  
*Sections or subsections omitted from the full prescribing information are not listed.  
PG324 Ophthalmic Soluti on  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 107 of 123  
   
 FULL PRESCRIBING INFORMATION 
1 INDICATIONS AND USAGE  
Latanoprost Sterile Ophthalmic Solution is indicated for the reduction of elevated intraocular 
press ure in patients with open- angle glaucoma or ocular hypertension.  
2 DOSAGE AND ADMINISTRATION  
The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose as normal.   
The dosage of latanoprost ophthalmic solution should not exceed once daily; the combined 
use of two or more prostaglandins, or prostaglandin analogs including latanoprost is not recommended. It has been shown that administration of these prostaglandin drug products more than once daily may decrease the intraocular pressure (IOP) lowering effect or cause paradoxical elevations in IOP.   
Reduction of the IOP starts approximately 3 to 4 hours after administration and the maximum effect is reached after 8 to  12 hours.   
Latanoprost ophthalmic solution may be used concomitantly with other topical ophthalmic drug products to lower IOP.  If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.  Contact lenses should be removed prior to the administration of latanoprost ophthalmic solution, and may be reinserted 15 minutes after administration.  
3 DOSAGE FORMS AND STRENGTHS  
Sterile ophthalmic solution containing 50 mcg/mL latanoprost. 
4 CONTRAINDICATIONS  
Known hypersensitivity to latanoprost, benzalkonium chloride, or any other ingredients in 
this product. 
5 WARNINGS AND PRECAUTIONS  
5.1 Pigmentation 
Latanoprost has been reported to cause changes to pigmented tissues. The most frequently 
reported changes have been increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes. Pigmentation is expected to increase as long as latanoprost is administered.  
The pigmentation change is due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes. After discontinuation of latanoprost, pigmentation of the iris is likely to be permanent, while pigmentation of the periorbital tissue and eyelash changes have been reported to be reversible in some patients . Patients who 
receive treatment should be informed of the possibility of increased pigmentation. Beyond 5 years the effects of increased pigmentation are not known [see Clinical Studies ( 14.2)]. 
Iris color change may not be noticeable for several months t o years. Typically, the brown 
pigmentation around the pupil spreads concentrically towards the periphery of the iris and 
PG324 Ophthalmic Soluti on  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 108 of 123  
   
 the entire iris or parts of the iris become more brownish.  Neither nevi nor freckles of the iris 
appear to be affected by treatment. W hile treatment with latanoprost can be continued in 
patients who develop noticeably increased iris pigmentation, these patients should be examined regularly [see Patient Counseling Information ( 17.1)]. 
5.2 Eyelash Changes 
Latanoprost may gradually change eyelashes and vellus hair in the treated eye; these changes 
include increased length, thickness, pigmentation, the number of lashes or hairs, and misdirected growth of eyelashes. Eyelash changes are usually reversible upon discontinuation of treatment [see Patient Counseling Information ( 17.2)]. 
5.3 Intraocular Inflammation 
Latanoprost should be used with caution in patients with a history of intraocular 
inflammation (iritis/uveitis) and should generally not be used in patients with active intraocular inflammation because inflammation may be exacerbated.  
5.4 Macular Edema 
Macular edema, including cystoid macular edema, has been reported during treatment with 
latanoprost. Latanoprost ophthalmic solution should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema. 
5.5 Herpetic Keratitis  
Reactivation of Herpes Simplex keratitis has been reported during treatment with latanoprost 
ophthalmic solution.  Latanoprost should be used with caution in patients with a history of herpetic keratitis. Latanoprost should be avoided in cases of active herpes simplex keratitis because inflammation may be exacerbated.  
5.6 Bacterial Keratitis  
There have been reports of bacteri al keratitis associated with the use of multiple -dose 
containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface [see Patient Counseling Information ( 17.3)]. 
5.7 Use with Contact Lenses 
Contact lenses should be removed prior to the administration of latanoprost ophthalmic 
solution, and may be reinserted 15 minutes after administration. 
6 ADVERSE REACTIONS  
The following adverse reactions were reported in postmarketing experience and are discussed 
in greater detail in other sections of the label:  
• Iris pigmentation changes [see Warnings and Precautions ( 5.1)] 
• Eyelid skin darkening [see Warnings and Precautions (5.1)] 
• Eyelash changes (increased length, thickness, pigmentation, and number of lashes) [see   Warnings and Precautions (5.2)] • Intraocular inflammation (iritis/uveitis) [see Warnings and Precautions (5.3)]  
PG324 Ophthalmic Soluti on  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 109 of 123  
   
 • Macular edema, including cystoid macular edema [see Warnings and Precautions ( 5.4)] 
6.1 Clinical Trials Experience  
Because clinical trials are conducted under widely varying conditions, the adverse reaction 
rates observed in the clinical studies of a drug cannot be directly compared to rates in t he 
clinical trials of another drug and may not reflect the rates observed in clinical practice.  
Latanoprost was studied in three multicenter, randomized, controlled clinical trials. Patients received 50 mcg/mL latanoprost once daily or 5 mg/mL active-compa rator (timolol)  
twice daily. The patient population studied had a mean age of 65±10 years. Seven percent of patients withdrew before the 6 -month endpoint. 
Table 1: Ocular Adverse Reactions and ocular signs/symptoms reported by 5–15% of 
patients receiving L atanoprost 
Symptom/Finding  
Adverse Reactions (incidence (%)  
Latanoprost  
(n = 460)  Timolol  
(n = 369)  
Foreign body sensation  13 8 
Punctate epithelial 
keratopathy  10 9 
Stinging  9 12 
Conjunctival hyperemia  8 3 
Blurred vision  8 8 
Itching  8 8 
Burning  7 8 
Increased pigmentation of 
the iris  7 0 
Less than 1% of the patients treated with latanoprost required discontinuation of therapy because of intolerance to conjunctival hyperemia.  
6.2 Postmarketing Experience 
The following reactions have been identified during postmarketing use of latanoprost in 
clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to latanoprost, or a combination of these factors, include: 
Nervous System Disorders : dizziness, headache, and toxic epidermal necrolysis  
Eye Disorders : eyelash and vellus hair changes (increased lengt h, thickness, pigmentation, 
and number); keratitis; corneal edema and erosions; intraocular inflammation (iritis/uveitis); macular edema, including cystoid macular edema; misdirected eyelashes sometimes resulting in eye irritation; periorbital and lid chan ges resulting in deepening of the eyelid sulcus. 
Respiratory, Thoracic and Mediastinal Disorder s: asthma and exacerbation of asthma; 
dyspnea 
PG324 Ophthalmic Soluti on  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 110 of 123  
   
 Skin and Subcutaneous Tissue Disorders: eyelid skin darkening Infections and Infestations: 
Herpes keratitis  
Table 2: Adverse Reactions that were reported in 1 –5% of patients receiving 
Latanoprost 
 Adverse Reactions (incidence (%))  
Latanoprost  
(n = 460)  Timolol  
(n = 369)  
Ocular Events/Signs and 
Symptoms    
Excessive tearing  4 6 
Lid discomfort/pain  4 2 
Dry eye  3 3 
Eye pain  3 3 
Lid crusting  3 3 
Lid erythema  3 2 
Photophobia  2 1 
Lid edema  1 3 
Systemic Events    
Upper respiratory tract 
infection/cold/flu  3 3 
Muscle/joint/back pain  1 0.5 
Rash/allergic skin reaction  1 0.3 
7 DRUG INTERACTIONS  
In vitro studies have shown that precipitation occurs when eye drops containing thimerosal 
are mixed with latanoprost.  If such drugs are used, they should be administered at least five (5) minutes apart.  
The combined use of two or more prostaglandins, or prostaglandin analogs including 
latanoprost is not recommended. It has been shown that administration of these prostaglandin drug products more than once daily may decrease the IOP lowering effect or cause paradoxical elevations in IOP.  
8 USE IN SPECIFIC POPULATIONS  
8.1 Pregnancy  
Teratogenic Effects: Pregnancy Category C.  
PG324 Ophthalmic Soluti on  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 111 of 123  
   
 Reproduction studies have been performed in rats and rabbits.  In rabbits, an incidence of 4 
of 16 dams had no viable fetuses at a dose that was approximately 80 times the maximum human dose, and the highest nonembryocidal dose in rabbits was approximately 15 times the maximum human dose. 
There are no adequate and well -controlled studies in pregnant women. Latanoprost should be 
used during pregnancy only if the potential benefit justifies the potential risk to the fetus.  
8.3 Nursing Mothers 
It is not known whether this drug or its metabolites are excreted in human milk. Because 
many drugs are excreted in human milk, caution should be exercised when latanoprost is administered to a nursing woman. 
8.4 Pediatric Use 
Safety and effectiveness in pediatric patients have not been established. 
8.5 Geriatric Use 
No overall differences in safety or effectiveness have been observed between elderly and 
younger patients. 
10 OVERDOSAGE  
Intravenous infusion of up to 3 mcg/kg in healthy volunteers produced mean plasma 
concentrations 200 times higher than during clinical treatment and no adverse reactions were observed.  Intravenous dosages of 5.5 to 10 mcg/kg caused abdominal pain, dizziness, fatigue, hot flushes, nausea, and sweating.  If overdosage with latanoprost occurs, treatment should be symptomatic. 
11 DESCRIPTION  
Latanoprost is a prostaglandin F2α analogue. Its chemical name is isopropyl- (Z)-
7[(1R,2R,3R,5S)3,5-dihydroxy-2- [(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-
heptenoate. Its  molecular formula is C26H40O5 and its chemical structure is: 
 
 
 
Latanoprost is a colorless to slightly yellow oil that is very  soluble in acetonitrile and freely 
soluble in acetone, ethanol, ethyl acetate, isopropanol, methanol, and octanol. I t is practically 
insoluble in water. 
Latanoprost ophthalmic solution 0.005% is supplied as a sterile, isotonic, buffered aqueous 
solution of latanoprost with a pH of approximately 6.7 and an osmolality of approximately 

PG324 Ophthalmic Soluti on  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 112 of 123  
   
 267 mOsmol/kg.  Each mL of Latanopros t ophthalmic solution contains 50 micrograms of 
latanoprost.  Benzalkonium chloride, 0.02% is added as a preservative.  The inactive  
ingredients are: sodium chloride, sodium dihydrogen phosphate monohydrate, disodium 
hydrogen phosphate anhydrous, and water  for injection.  One drop contains approximately 
1.5 mcg of latanoprost. 
12 CLINICAL PHARMACOLOGY  
12.1 Mechanism of Action 
Latanoprost is a prostanoid selective FP receptor agonist that is believed to reduce the 
intraocular pressure (IOP) by increasing the outflow of aqueous humor. Studies in animals and man suggest that the main mechanism of action is increased uveoscleral outflow. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likeliho od of optic nerve damage and visual field loss. 
12.2 Pharmacodynamics 
Reduction of the IOP in man starts about 3–4 hours after administration and maximum effect 
is reached after 8 –12 hours. IOP reduction is present for at least 24 hours. 
12.3 Pharmacokinet ics 
Absorption 
Latanoprost is absorbed through the cornea where the isopropyl ester prodrug is hydrolyzed to the acid form to become biologically active.  
Distribution  
The distribution volume in humans is 0.16 ± 0.02 L/kg. The acid of latanoprost can be measured in aqueous humor during the first 4 hours, and in plasma only during the first hour after local administration. Studies in man indicate that the peak concentration in the aqueous humor is reached about two hours after topical administration. 
Metaboli sm 
Latanoprost, an isopropyl ester prodrug, is hydrolyzed by esterases in the cornea to the biologically active acid. The active acid of latanoprost reaching the systemic circulation  
is primarily metabolized by the liver to the 1,2 -dinor and 1,2,3,4- tetran or metabolites via 
fatty acid β -oxidation. 
Excretion  
The elimination of the acid of latanoprost from human plasma is rapid (t1/2 = 17 min) after both intravenous and topical administration. Systemic clearance is approximately 7 mL/min/kg. Following hepatic  β-oxidation, the metabolites are mainly eliminated via the 
kidneys. Approximately 88% and 98% of the administered dose are recovered in the urine after topical and intravenous dosing, respectively. 
PG324 Ophthalmic Soluti on  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 113 of 123  
   
 13 NONCLINICAL TOXICOLOGY  
13.1 Carcinogenesis, Mutagenesi s, Impairment of Fertility  
Latanoprost was not carcinogenic in either mice or rats when administered by oral gavage at 
doses of up to 170 mcg/kg/day (approximately 2800 times the recommended maximum human dose) for up to 20 and 24 months, respectively. 
Latanoprost was not mutagenic in bacteria, in mouse lymphoma, or in mouse micronucleus 
tests. Chromosome aberrations were observed in vitro with human lymphocytes.  Additional 
in vitro and in vivo studies on unscheduled DNA synthesis in rats were negative. 
Latanoprost has not been found to have any effect on male or female fertility in animal 
studies. 
14 CLINICAL STUDIES  
14.1 Elevated Baseline IOP 
Patients with mean baseline IOP of 24 – 25 mmHg who were treated for 6 months in multi-
center, randomized, control led trials demonstrated 6 – 8 mmHg reductions in IOP. This IOP 
reduction with latanoprost 0.005% dosed once daily was equivalent to the effect of timolol 0.5% dosed twice daily. 
14.2 Progression of Increased Iris Pigmentation 
A 3-year open -label, prospective safety study with a 2 -year extension phase was conducted to 
evaluate the progression of increased iris pigmentation with continuous use of latanoprost 
once-daily as adjunctive therapy in 519 patients with open- angle glaucoma. The analysis was 
based on observed -cases population of the 380 patients who continued in the extension 
phase.  Results showed that the onset of noticeable increased iris pigmentation occurred within the first year of treatment for the majority of the patients who developed noticeabl e 
increased iris pigmentation. Patients continued to show signs of increasing iris pigmentation throughout the five years of the study. Observation of increased iris pigmentation did not affect the incidence, nature, or severity of adverse events (other than increased iris pigmentation) recorded in the study.  IOP reduction was similar regardless of the development of increased iris pigmentation during the study. 
16 HOW SUPPLIED/STORAGE AND HANDLING  
Latanoprost ophthalmic solution is a clear, isotonic, buffered, preserved colorless solution of 
latanoprost 0.005% (50 mcg/mL).  It is supplied as a 2.5 mL solution in a 4 mL clear low density polyethylene bottle with a low density polyethylene dropper tip, and a turquoise high density polypropylene screw cap, and a clear PVC film with a single perforation.  
2.5 mL fill, 0.005% (50 mcg/mL): Package of 1 bottle: 
NDC 24208-463-25 Storage: Protect from light. Store unopened bottle(s) under refrigeration at 2° to 8°C (36° to 
46°F). During shipment to the patient, the bottle may be maintained at temperatures up to  
40°C (104°F) for a period not exceeding 8 days. Once a bottle is opened for use, it may be stored at room temperature up to 25°C (77°F) for 6 weeks. 
PG324 Ophthalmic Soluti on  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 114 of 123  
   
 17 PATIENT COUNSELING INFORMATION 
17.1 Potential for Pigmentation  
Advise patients about the potential for increased brown pigmentation of the iris, which may 
be permanent. Inform patients about the possibility of eyelid skin darkening, which may be reversible after discontinuation of Latanoprost ophthalmic solution [see Warnings and Precautions ( 5.1)]. 
17.2 Potential for Eyelash Changes 
Inform patients of the possibility of eyelash and vellus hair changes in the treated eye during 
treatment with Latanoprost ophthalmic solution. These changes may result in a disparity between eyes in length, thickness, pigmentation, number of eyelashes or vellus hairs, and/or direction of eyelash growth.  Eyelash changes are usually reversible upon discontinuation of treatment.  
17.3 Handling the Container 
Instruct patients to avoid allowing the tip of the dispensing container to contact the eye or 
surrounding structures because this could cause the tip to become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions [see Warnings and Precautions ( 5.6)]. 
17.4 When to Seek Physician Advice 
Advise patients that if they develop an intercurrent ocular condition (e.g., trauma or 
infection) or have ocular surgery, or develop any ocula r reactions, particularly conjunctivitis  
and eyelid reactions, they should immediately seek their physician’s advice concerning the continued use of the multiple-dose container. 
17.5 Use with Contact Lenses 
Advise patients that Latanoprost ophthalmic solution contains benzalkonium chloride, which 
may be absorbed by contact lenses. Contact lenses should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of Latanoprost ophthalmic solution. 
17.6 Use with Other Ophthalmic Drugs  
If more than one topical ophthalmic drug is being used, the drugs should be administered at 
least five (5) minutes apart.  
Manufactured By:  
Bausch & Lomb Incorporated  
Tampa, Florida 33637 ©Bausch & Lomb Incorporated     9144705 (folded) 
Revised: February 2015     9144805 (flat) 
 
 
PG324 Ophthalmic Soluti on  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 115 of 123  
   
 Appendix  4 Sponsor’s Obligations 
Aerie Pharmaceuticals, Inc. is committed to:  
1. Complying with the local health authority regulations for the conduct of clinical research 
studies. 
2. Informing the Investigator of any new information about the investigational product that may affect the subject's welfare or may influence the subject 's decision to continue 
participation in the study.  
3. In the event of a serious adverse experience, whether related to the use of the study medication or device or not, or the death of a subject, the Sponsor is responsible for notifying the regulatory authority(ies) immediately (see Section  6.9, Adverse events ).  
4. When the study is terminated the Sponsor should promptly inform the regulatory authority(ies) of the termination and the reason(s) for it. The IRB should also be informed 
promptly and provide the reason(s) for the termination by the Sponsor as specified by the applicable re gulatory requirement(s).  
5. Providing to the Investigator the most up- to-date editions of the Clinical Investigator’s 
Brochure  (for the investigational product), the protocol, Serious Adverse Experience 
forms, and a full set of Case Report Forms for each subject  entered into the study to 
document the study evaluation parameters. 
6. Providing study medications suitably masked/blinded, coded and packaged for use with subject s entered into the study. 
7. Providing statistical and report writing resources to complete ap propriate reporting of 
study results.  
8. Ensuring equity considerations among all Investigators in multicenter studies, including all matters of publications and meeting presentations, etc. (where applicable).  
9. Prepare an FDA Form N o. 3454 (Certification: Financial Interests and Arrangements of 
Clinical Investigators) or 3455 (Disclosure: Financial Interests and Arrangements of Clinical Investigators) or Sponsor’s equivalent.
PG324 Ophthalmic Soluti on  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 116 of 123  
   
 Appendix  5 Investigator’s Obligations  
The Investigator is obligated to: 
1. In the event of a serious adverse experience, whether related to the use of the study 
medication or device or not, or the death of a subject, the Investigator is responsible for notifying the Sponsor Safety Offic er immediately (see Section  6.9, Adverse events ). 
The Investigator must also notify the Sponsor Representative and the Institutional 
Review Board (IRB) to which he/she is responsible. 
2. Prior to initiating the study, sign and return to the Sponsor Representati ve, the relevant 
form (Statement of Investigator form provided by the Sponsor for studies involving non-significant risk devices, or OTC drugs; or an FDA No. 1572 is required for IND Phase I, II, III and IV studies). Each sub -Investigator who will assist in the study is to be 
identified in the required form. The current curriculum vitae (signed and dated) of the principal Investigator and of each sub-Investigator named in the Statement of Investigator form or 1572 form is to accompany the form.  
3. Cooperate w ith the Sponsor on the preparation of an FDA Form No. 3454 
(Certification: Financial Interests and Arrangements of Clinical Investigators) or 3455 (Disclosure: Financial Interests and Arrangements of Clinical Investigators).  
4. Obtain and submit to the Sponsor a copy of his/her IRB approval of the protocol prior to initiating the study.  
5. Obtain signed informed consent from each subject  or his/her legal guardian prior to 
acceptance of the subject  into the study. 
6. Read, and agree to adhere to the study protocol prior to the initiation of the study. Deviations from the study protocol are not to be implemented without the prior written approval of the Sponsor and IRB , unless protection of the safety and welfare of study 
subject s requires prompt action. During the study, if the Investigator feels that in his/her 
clinical judgment, it is necessary to promptly terminate one or more subject s from the 
study, or to promptly implement reasonable alternatives to, or deviations from the protocol in consideration of the safety of study subject s, the Sponsor is to be notified of 
these terminations, alternatives, and deviations, and the reasons for such changes are to be documented in the study records. The Investigator is to also notify his/her IRB of any such changes.  
7. Accurately record, at the Investigator’s site, all required data on each subject 's electronic 
Case Report Form.   
8. Replace subject s consistent with the directions in Section  4.4. 
  
PG324 Ophthalmic Soluti on  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 117 of 123  
   
 9. Keep accurate records of the number of study medication or device units received from 
the Sponsor and dispensed or administered to each subject  during the study, and return 
any unused study medication or devices to the Sponsor at the completion of the study. Before returning the study medications or devices to the Sponsor, a detailed inventory should be recorded and placed in the Investigator’s file. 
10. Assure that Investigational Products will be dispensed or administered only to subject s 
under his/her personal supervision, or under the supervision of authorized sub-Investigators responsible to him/her. 
11. Allow a representative of the Sponsor and/or representatives of health regulatory agencies to inspect all Case Report Forms and corresponding portions of each study 
subject 's source documentation (ie, origi nal office, hospital, and laboratory records) 
at mutually convenient times at regular intervals during the study, and upon request after 
the study has been completed. The purpose of these on- site monitoring visits is to provide 
the Sponsor the opportunity to evaluate the progress of the study, document compliance with the protocol and with regulatory requirements, verify the accuracy and completeness of subject  electronic Case Report Forms, resolve any apparent discrepancies or 
inconsistencies in the study records, and account for all investigational supplies. 
12. Provide the governing IRB with a brief (ie, one to three pages) Investigator's summary within 90 working days of the study completion.  
13. Complete the study within the time limits agreed upon with the Sp onsor prior to the 
initiation of the study.  
14. Maintenance of records  
a. Disposition of drug. An investigator is required to maintain adequate records of the disposition of the drug, including dates, quantity, and use by subject s. 
If the investigation is termina ted, suspended, discontinued, or completed, the 
investigator shall return the unused supplies of the drug to the Sponsor, or otherwise provide for disposition of the unused supplies of the drug under 21 CFR 312.59.  
b. Case histories. An investigator is required to prepare and maintain adequate and accurate case histories that record all observations and other data pertinent to the investigation on each individual administered the investigational drug or employed as a control in the investigation. Case histori es include the case 
report forms and supporting data including, for example, signed and dated consent forms and medical records including, for example, progress notes of the physician, the individual's hospital chart(s), and the nurses' notes. The case history for each individual shall document that informed consent was obtained prior to participation in the study.  
c. Record retention. An investigator shall retain records required to be maintained under this part for a period of 2 years following the date a 
PG324 Ophthalmic Soluti on  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 118 of 123  
   
 marketing application is approved for the drug for the indication for which it 
is being investigated; or, if no application is to be filed or if the application is not approved for such indication, until 2 years after the investigation is discontinued and F DA is notified.   
These documents should be retained for a longer period however if required by the applicable regulatory requirements or by an agreement with the Sponsor. 
If for any reason the Investigator withdraws from the responsibility of maintaining the study 
records for the required period of time, custody of the records may be transferred to any other person who will accept responsibility for the records. The Sponsor is to be notified in writing of any such transfer.  
PG324 Ophthalmic Soluti on  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 119 of 123  
   
 Appendix  6 Declaration of Helsinki  
Recommendations Guiding Medical Doctors in Biomedical Research Involving Human 
Subject s 
I. BASIC PRINCIPLES  
1. Biomedical research involving human subjects must conform to generally accepted scientific principles and should be ba sed on adequately performed laboratory and animal 
experimentation and on a thorough knowledge of the scientific literature. 
2. The design and performance of each experimental procedure involving human subject s 
should be clearly formulated in an experimental p rotocol which should be transmitted to 
a specially appointed independent committee for consideration, comment and guidance. 
3. Biomedical research involving human subject s should be conducted only by scientifically 
qualified persons and under the supervision of a clinicall y competent medical person. 
The responsibility for the human subject  must always rest with a medically qualified 
person and never rest with the subject  of the research, even though the subject  has given 
his or her consent. 
4. Biomedical research  involving human subject s cannot legitimately be carried out unless 
the importance of the objective is in proportion to the inherent risk to the subject . 
5. Every biomedical research project involving human subject s should be preceded by 
careful assessment of  predictable risks in comparison with foreseeable benefits to the 
subject  or to others. Concern for the interests of the subject  must always prevail over the 
interests of science and society.  
6. The right of the research subject  to safeguard his or her integr ity must always be 
respected. Every precaution should be taken to respect the privacy of the subject  and to 
minimize the impact of the study on the subject's physical and mental integrity and on the 
personality of the subject . 
7. Doctors should abstain from engaging in research projects involving human subject s 
unless they are satisfied that the hazards involved are beli eved to be predictable. 
Doctors should cease any investigation if the hazards are found to outweigh the potential benefits.  
8. In publication of the results of his or her research, the doctor is obliged to preserve the accuracy of the results. Reports of experimentation not in accordance with the principles laid down in this Declaration should not be accepted for publication. 
9. In any research on human beings, each potential subject  must be adequately informed of 
the aims, methods, anticipated benefits and potential hazards of the study and the discomfort it may entail. He or she should be informed that he or she is at liberty to 
PG324 Ophthalmic Soluti on  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 120 of 123  
   
 abstain from particip ation in the study and that he or she is free to withdraw his or her 
consent to participation at any time. The doctor should then obtain the subject 's given 
informed consent, preferably in writing. 
10. When obtaining informed consent for the research project the doctor should be 
particularly cautious if the subject  is in a dependent relationship to him or her or may 
consent under duress. In that case, the informed consent should be obtained by a doctor who is not engaged in the investigation and who is completely independent of this official relationship. 
11. In case of legal incompetence, informed consent should be obtained from the legal guardian in accordance with national legislation. Where physical or mental incapacity makes it impossible to obtain informed con sent, or when the subject  is a minor, 
permission from the responsible relative replaces that of the subject  in accordance with 
national legislation.  
12. The research protocol should always contain a statement of the ethical considerations involved and should i ndicate that the principles enunciated in the present Declaration are 
complied with.  
II. MEDICAL RESEARCH COMBINED WITH PROFESSIONAL CARE (CLINICAL RESEARCH)  
13. In the treatment of the sick person, the doctor must be free to use a new diagnostic and therapeut ic measure, if in his or her judgment it offers hope of saving life, reestablishing 
health or alleviating suffering.  
14. The potential benefits, hazards and discomforts of a new method should be weighed against the advantages of the best current diagnostic and therapeutic methods.  
15. In any medical study, all subject s - including those of a control group, if any, should be 
assured of the best proven diagnostic and therapeutic methods. 
16. The refusal of the subject to participate in a study must never interfere with the 
doctor- subject  relationship. 
17. If the doctor considers it essential not to obtain informed consent, the specific reasons for this proposal should be stated in the experimental protocol for transmission to the independent committee. 
18. The doctor can combine medical research with professional care, the objective being the 
acquisition of new medical knowledge, only to the extent that medical research is justified by its potential diagnostic or therapeutic value for the subject. 
  
PG324 Ophthalmic Soluti on  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 121 of 123  
   
 III. NON -THERAPEUTIC BIOMEDICAL  RESEARCH INVOLVING HUMAN 
SUBJECT  (NONCLINICAL BIOMEDICAL RESEARCH)  
19. In the purely scientific application of medical research carried out on a human being, it is 
the duty of the doctor to remain the protector of the life and health of that person on whom bi omedical research is being carried out.  
20. The subject s should be volunteers - either healthy person or subject s for whom the 
experimental design is not related to the subject 's illness.  
21. The Investigator or the team should discontinue the research if in his/her or their judgment it may, if continued, be harmful to the individual.  
22. In research on man, the interest of science and society should never take precedence over consideration related to the well -being of the subject .
PG324 Ophthalmic Soluti on  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 122 of 123  
   
 Appendix  7 Sample SAS Code  
The following SAS code will be used for multiple imputations using the Monte- Carlo 
Markov Chain method, where a separate model will be fit for each time point at each visit. 
proc mi data = indata seed = 48669 out = outdata1; 
     mcmc initial = em; 
     var trt01pn baseline IOP ; 
run; 
 
where  
- indata is the name of the input dataset 
- outdata1 is the name of the output dataset 
- trt01pn is the name of the treatment group variable in numeric format  
- baseline  captures the baseline IOP for th e given time point 
- IOP is the name of the IOP measure.  
Five complete data sets will be generated from the above code. Each complete data set will 
be used to analyze this primary efficacy endpoint separately using analysis of variance. Then, the SAS proce dure MIANALYZE will be used to analyze the results from the 5 complete 
data sets to generate a combined inference. The following SAS code will be used:  
 
ods output diffs = outdata2; 
proc mixed data= outdata1; 
 by _IMPUTATION _; 
 class trt01pn; 
 model IOP  = trt01pn baseline ; 
 lsmeans trt01pn / cl pdiff; 
run; 
 
proc sort data= outdata2;  by trt01pn _trt01pn; 
run; 
 
ods output ParameterEstimates = outdata3; 
proc mianalyze data= outdata2 alpha = 0.05; 
 by trt01pn _trt01pn; 
 class trt01pn _trt01pn; 
 modeleffects es timate; 
 stderr;  
PG324 Ophthalmic Soluti on  
Clinical Study Protocol: PG324 -CS30 1, Amendment 4  Aerie Pharmaceuticals, Inc.  
 
   
Confidential  Page 123 of 123  
   
 run; 
where  
- outdata1 is the name of the input dataset from Proc MI 
- _IMPUTATION_  is the imputation number 
- trt01pn is the name of the treatment group variable in numeric format  
- IOP is the name of the IOP measure  
- baseline  captures t he baseline IOP for the given time point 
- outdata2 is the name of the output dataset that contains the statistical results of the 
difference between treatment groups  
- outdata3 is the name of the output dataset that contains summary and inferential statistics.  
 